Author: "Consoli, D." / Publication Year Range: Last 10 years - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Consoli, D."' showing total 95 results

Start Over Author "Consoli, D." Publication Year Range Last 10 years

95 results on '"Consoli, D."'

1. Probing Fuzzballs with Particles, Waves and Strings

Author: Bianchi, M., Consoli, D., and Morales, J. F.
Subjects: High Energy Physics - Theory
Abstract: We probe D1D5 micro-state geometries with massless particles, waves and strings. To this end, we study geodetic motion, Klein-Gordon equation and string scattering in the resulting gravitational background. Due to the reduced rotational symmetry, even in the simple case of a circular fuzzball, the system cannot be integrated elementarily. Yet, for motion in the plane of the string profile or in the orthogonal plane to it, one can compute the deflection angle or the phase shift and identify the critical impact parameter, at which even a massless probe is captured by the fuzzball if its internal momentum is properly tuned. We find agreement among the three approaches, thus giving further support to the fuzzball proposal at the dynamical level., Comment: 35 pages. Extended and improved discussions on the integrability of the geodetic equations and on the critical impact parameters
Published: 2017
Full Text: View/download PDF

2. Medical and endovascular treatments of symptomatic intracranial stenosis. A Bayesian network meta-analysis

Author: Vidale, S., Agostoni, E., Grampa, G., Consoli, A., and Consoli, D.
Published: 2019
Full Text: View/download PDF

3. Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial

Author: Abdelhamid, N, Abdul Rahman, D, Abdul-Saheb, M, Abreu, P, Abroskina, M, Abu Ahmad, F, Accassat, S, Acciaresi, M, Adami, A, Ahmad, N, Ahmed, F, Alberto Hawkes, M, Alemseged, F, Ali, A, Altavilla, R, Alwis, L, Amarenco, P, Amaro, S, Amaya Sanchez, LE, Amelia Pinto, A, Ameriso, SF, Amin, H, Amino, T, Amjad, AK, Anagnostou, E, Andersen, G, Anderson, C, Anderson, DC, Andrea Falco, M, Andres Mackinnon, F, Andreu, D, Androulakis, M, Angel Gamero, M, Angel Saredo, G, Angeles Diaz, R, Angels Font, M, Anticoli, S, Arauz, A, Arauz Gongora, AA, Araya, P, Arenillas Lara, JF, Arias Rivas, S, Arnold, M, Augustin, S, Avelar, W, Azevedo, E, Babikian, V, Bacellar, A, Badalyan, K, Bae, HJ, Baez Martinez, EM, Bagelmann, H, Bailey, P, Bak, Z, Baker, M, Balazs, A, Baldaranov, D, Balogun, I, Balueva, T, Bankuti, Z, Bar, M, Baranowska, A, Bardutzky, J, Barker Trejo, S, Barlinn, J, Baronnet, F, Barroso, C, Barteys, M, Bartolottiova, T, Barulin, A, Bas, M, Bashir, S, Basile, V, Bathe-Peters, R, Bathula, R, Batista, C, Batur Caglayan, H, Baumgartner, P, Bazan, R, Bazhenova, O, Beaudry, M, Beer, J, Behnam, Y, Beilei, C, Beinlich, A, Bejot, Y, Belkin, A, Benavente, OR, Benjamin, A, Berardi, V, Bereczki, D, Berkowitz, SD, Berlingieri, J, Berrios, W, Berrouschot, J, Bhandari, M, Bhargavah, M, Bicker, H, Bicsak, T, Bilik, M, Bindila, D, Birchenall, J, Birnbaum, L, Black, T, Blacker, D, Blacquiere, D, Blanc-Labarre, C, Blank, C, Blazejewska-Hyzorek, B, Bloch, S, Bodiguel, E, Bogdanov, E, Boos, L, Borcsik, L, Bornstein, N, Bouly, S, Braga, G, Bragado, I, Bravi, MC, Brokalaki, C, Brola, W, Brouns, R, Bruce, D, Brzoska-Mizgalska, J, Buck, B, Buksinska-Lisik, M, Burke, J, Burn, M, Bustamante, G, Cabrejo, L, Cai, K, Cajaraville, S, Calejo, M, Calvet, D, Campillo, J, Campos Costa, E, Camps, P, Can Alaydin, H, Candeloro, E, Canepa, C, Cantu Brito, CG, Cappellari, M, Carcel, C, Cardona Portela, P, Cardoso, F, Carek, M, Carletti, M, Carlos Portilla, J, Caruso, P, Casado-Naranjo, I, Castellini, P, Castro, D, Castro Meira, F, Cavallini, A, Cayuela Caudevilla, N, Cenciarelli, S, Cereda, C, Cerrone, P, Chakrabarti, A, Chaloulos-Iakovidis, P, Chamorro, A, Chandrasena, D, Chang, DI, Che, C, Chembala, J, Chen, J, Chen, Z, Chen, T, Chen, H, Chen, X, Chen, G, Chen, L, Chen, S, Cheripelli, B, Chin, M, Chiquete Anaya, E, Chorazy, M, Christensen, H, Christensen, T, Christian, L, Chu, F, Chung, CS, Clark, W, Clarke, R, Claverie, S, Clemente Agostoni, E, Clissold, B, Coelho, J, Cohen, D, Colakoglu, S, Collas, D, Condurso, R, Connolly, SJ, Consoli, D, Constantin, C, Constantino Silva, AB, Contardo, L, Corlobe, A, Correia, M, Correia, C, Cortijo Garcia, E, Coull, B, Coutts, S, Coveney, S, Cras, P, Crols, R, Crozier, S, Csanyi, A, Csiba, L, Csontos, K, Csuha, R, Cui, L, Cunha, L, Curtze, S, Czerska, M, Czlonkowska, A, Czurko, M, Czuryszkiewicz, M, Dagnino, M, Dai, C, Daineko, A, Dalek, G, Damgaard, D, Danese, A, Dani, K, Danku, V, Dario Toledo, W, Dávalos, A, De Havenon, A, De Keyser, J, De Klippel, N, De La Torre, J, De Pauw, A, De Smedt, A, De Torres, R, De Vries Basson, MM, Dearborn, J, Deganutto, R, Degeorgia, M, Deguchi, I, Del Giudice, A, Delcourt, C, Delgado-Mederos, R, Della Marca, G, Delpont, B, Deltour, S, Demets, DL, Dennis, M, Desai, J, Devine, J, Dhollander, I, Di Mascio, MT, Diaconu, M, Diaz Otero, F, Dietzel, J, Diez-Tejedor, E, Ding, N, Ding, J, Diomedi, M, Dioszeghy, P, Distefano, M, Domigo, V, Dorodnicov, E, Dossi, D, Doubal, F, Druzenko, I, Du, P, Du, J, Duman, T, Duodu, Y, Dutta, D, Dylewicz, L, Eckstein, J, Ehrensperger, E, Ehrlich, S, Einer Allende, G, Elena Halac, B, Elyas, S, Endres, M, Engelbrecht, JM, Engelter, S, Epinat, M, Eren, F, Esbjornsson, M, Escribano, B, Escudero, I, Esisi, B, Essa, B, Esterbauer, M, Evans, N, Eveson, D, Fabio, S, Fang, L, Fanta, S, Fares, M, Fatar, M, Faust, K, Favate, A, Fazekas, F, Federica Denaro, M, Fedin, A, Felipe Amaya, P, Feng, J, Ferencova, K, Fernanda Gilli, M, Fernandez, MD, Fernandez Pirrone, PN, Fernandez Vera, J, Ferrari, J, Ferreira, A, Ferreira Junior, G, Fidler, M, Field, D, Field, T, Figueroa, C, Fiksa, J, Filipov, A, Firstenfeld, A, Fisch, L, Fischer, U, Fisselier, M, Fiszer, U, Fluri, F, Fortea, G, Fotherby, K, Fraczek, A, France, E, Freitas, G, Frey, S, Frick, M, Friedman, A, Friedrich, M, Frisullo, G, Fryze, W, Fuentes Gimeno, B, Fujigasaki, H, Fukuyama, K, Furlan, A, Furlanis, G, Furnace, J, Gabriel, M, Gabriel Reich, E, Gagliardi, RJ, Galati, F, Galli Giqueauk, E, Gallina, A, Gallinella, E, Gallo, J, Gangadharan, S, Gao, Y, Garcia Lopez, R, Garcia Pastor, A, Garcia Sanchez, SM, Garnauf, M, Garnier, P, Gasecki, D, Gasic, K, Gasiorek, K, Gasser, S, Gaugg, M, Gebreyohanns, M, Gebura, K, Geng, J, Geniz Clavijo, M, Georg Haeusler, K, Geran, R, Geremek, M, Gerocs, Z, Ghia, D, Giannandrea, D, Giatsidis, F, Gien Lopez, JA, Gil Nunez, A, Gimenez, L, Giralt, E, Glabinski, A, Gladstone, D, Gliem, M, Gluszkiewicz, M, Goddeau, R, Gogoleva, E, Gokce, M, Goldemund, D, Golikov, K, Gomes Neto, A, Gomez Schneider, M, Gomez-Choco, M, Gomis, M, Gongora-Rivera, JF, Gonysheva, Y, Gonzalez, L, Gonzalez Toledo, ME, Gottschal, M, Gozdzik, I, Grabowski, S, Graf, S, Green, D, Greer, D, Gregorio, T, Greisenegger, S, Greshnova, I, Griebe, M, Grzesik, M, Guan, J, Guarda, S, Gueguen, A, Guidoux, C, Guillermo Povedano, P, Guillon, B, Guiraudg, V, Gunathilagan, G, Guryanova, N, Gusev, V, Gustavo Persi, G, Gutiérrez, R, Guyler, P, Gyuker, N, Hachinski, V, Hajas, A, Hallevi, H, Hankey, G, Hankey, GJ, Hanouskova, L, Hao, L, Haraguchi, K, Haralur Sreekantaiah, Y, Haratz, S, Hargroves, D, Harkness, K, Harmel, P, Harrasser, M, Hart, RG, Harvey, M, Hasan, R, Hasegawa, Y, Hassan, A, Hattori, M, Hatzitolios, A, Hauk, M, Hayashi, T, Hayhoe, H, Hedna, VS, Heine, M, Held, V, Hellwig, S, Henkner, J, Henninger, N, Hermans, S, Hernandez, J, Herrero, D, Hervieu-Begue, M, Herzig, R, Hicken, L, Hieber, M, Hill, M, Hirose, M, Hobeanu, MC, Hobson, B, Hochstetter, M, Hoe Heo, J, Hoffmann, M, Holmstedt, C, Hon, P, Hong, KS, Honma, Y, Horev, A, Horgan, G, Horvath, L, Horvath, M, Hoyer, C, Huang, D, Huang, H, Huber, B, Huhtakangas, J, Hussain, M, Igarashi, S, Iglesias Mohedano, AM, Ignacio Tembl, J, Impellizzeri, M, Inanc, Y, Ioli, P, Irina Aniculaesei, A, Ishida, K, Itabashi, R, Iversen, H, Jagolino, A, Jakab, K, Jander, S, Janka, H, Jankovych, J, Jansen, J, Jasek, L, Javier Alet, M, Javor, L, Jin, X, Jing, P, Joachim, B, Joan Macleod, M, Johnson, M, Jose Martin, J, Joyner, C, Judit Szabo, K, Jun-Oconnell, A, Jura, R, Kaczorowska, B, Kadlcikova, J, Kahles, T, Kakaletsis, N, Kakuk, I, Kalinowska, K, Kaminska, K, Kaneko, C, Kanellos, I, Kapeller, P, Kapica-Topczewska, K, Karasz, O, Karlinski, M, Karlsson, JE, Kasa, K, Kashaeva, E, Kasner, SE, Kaste, M, Kasza, J, Katalin Iljicsov, A, Katsurayama, M, Kaur, S, Kawanishi, M, Kaygorodtseva, S, Ke, K, Kei, A, Keilitz, J, Kellner, J, Kelly, P, Kelly, S, Kemlink, D, Kerekgyarto, M, Keskinarkaus, I, Khairutdinova, D, Khanna, A, Khaw, A, Kholopov, M, Khoumri, C, Kirpicheva, S, Kirshner, H, Kitagawa, K, Kittner, S, Kivioja, R, Klein, F, Kleindorfer, D, Kleinig, T, Klivenyi, P, Knecht, S, Kobayashi, Y, Kobayashi, A, Koch, M, Koehler, L, Koivu, M, Kolianov, V, Koltsov, I, Kondo, T, Konkov, I, Kopecky, S, Korompoki, E, Korpela, J, Kosarz-Lanczek, K, Koutroubi, A, Kovacs, K, Kovacs, T, Kovacs, H, Kowalczyk, K, Kowalska, M, Krajickova, D, Kral, M, Krarup Hansen, C, Kraska, J, Krebs, S, Krejci, V, Kremer, C, Kreuzpointer, R, Krzyzanowska, M, Kucken, D, Kulakowska, A, Kunzmann, J, Kurenkova, N, Kuris, A, Kurkowska-Jastrzebska, I, Kurtenkova, N, Kurushina, O, Kusnick, G, Kustova, M, Kuwashiro, T, Kwan Cha, J, Lago, A, Lagutenko, M, Lajos, B, Lambeck, J, Lamy, C, Landolfi, A, Lanfranconi, S, Lang, W, Lara Lezama, LB, Lara Rodriguez, B, Largo, T, Lasek-Bal, A, Latte, L, Lauer, V, Lavados, P, Le Bouc, R, Leal Cantu, R, Lechner, H, Lecouturier, K, Leder, S, Lee, J, Lee, BC, Leger, A, Leira, E, Leisse, I, Leker, R, Lembo, G, Lenskaya, L, Leyden, J, Li, G, Li, M, Li, S, Li, J, Liamis, G, Liang, H, Liang, Z, Ligot, N, Lin, H, Lindert, R, Lindgren, A, Linna, M, Litwin, T, Liu, K, Liu, X, Llull, L, Lohninger, B, Longoni, M, Loomis, C, Lopes, D, Lopez Fernandez, M, Lopez Garza, N, Lord, A, Louw, S, Lovasz, R, Lowenkopf, T, Lu, Z, Lubke-Detring, SC, Luder, R, Lujan, S, Luo, B, Lupinogina, L, Luschin, G, Lutsep, H, Lvova, A, Ly, J, Grosse, G.M., Ma, H, Ma, C, Machado, M, Machado, C, Macher, S, Machetanz, J, Macian-Montoro, F, Mackey, E, Mackey, A, Maclean, G, Maestre-Moreno, J, Magadan, A, Magyar, T, Mahagney, A, Majid, A, Majjhoo, A, Makaritsis, K, Mandzia, J, Mangas Guijarro, M, Mangion, D, Manios, E, Mann, S, Manning, L, Manno, C, Manuel Garcia, J, Maqueda, V, Mar Castellanos, M, Mar Freijo, M, Marando, C, Marcela Lepera, S, Marcos Couto, J, Maria Bruera, G, Maria Greco, L, Maria Lorenzo, A, Maria Obmann, S, Maria Roa, A, Marini, C, Marinkovic, I, Mario Sumay, G, Mario Torres, C, Marko, M, Markova, S, Markus, H, Marsh, R, Marsili, E, Marta Esnaola, M, Marta Moreno, J, Marti-Fabregas, J, Martina Angelocola, S, Martínez Sánchez, P, Martinez-Majander, N, Martins, S, Marzelik, O, Mastrocola, S, Matamala, G, Matoltsy, A, Matosevic, B, Matsumoto, S, Maud, A, Mauri Cabdevila, G, May, Z, Mayasi, Y, Mayr, A, Mazzoli, T, Mcarthur, K, Mccullough, L, Medina Pech, CE, Medlin, F, Mehdiratta, M, Mehta, S, Mehta, D, Mehta, B, Melis, M, Melnikova, E, Mendez, B, Mendonca, T, Mengual Chirifie, JJ, Menon, N, Mensch, A, Meseguer, E, Messe, S, Metcalf, K, Meyer, N, Michas, F, Micheletti, N, Mikulik, R, Milionis, H, Miller, B, Milling, T, Minelli, C, Minhas, J, Minns, M, Mircea, D, Mishra, S, Mismas, A, Mistri, A, Mitrovic, N, Miyake, H, Modrau, B, Moey, A, Molina, C, Molina, J, Molis, A, Moller, J, Molnar, S, Moniche, F, Monosi, C, Monzani, V, Moonis, M, Morais, R, Morales, L, Morales, A, Morar-Precup, D, Moreton, F, Moro, C, Morozova, E, Morton, M, Morvan, T, Morvan, E, Motko, T, Mowla, A, Mozhejko, E, Muddegowda, G, Mudhar, O, Mueller, T, Muhl, C, Muir, KW, Mundl, H, Munoz, S, Murphy, C, Murphy, S, Murtuzova, A, Musuka, T, Mutzenbach, J, Myint, M, Mysliwy, W, Naccarato, M, Naeije, G, Nagakane, Y, Natarajan, I, Navaratnam, D, Nave, A, Nazliel, B, Nedeltchev, K, Nel, J, Nell, H, Nemeth, R, Nemeth, L, Neto, O, Ng, K, Ngeh, J, Nicolas Chialvo, L, Nieminen, T, Nikkanen, M, Nikl, J, Nikoforova, M, Nishino, S, Nishiyama, Y, Njovane, X, Nogawa, S, Nombela, F, Norrving, B, Nosek, K, Nowak, B, Nowakowska-Sledz, E, Ntaios, G, Numminen, H, Nunez, F, Obadia, M, Oberndorfer, S, Obrezan, A, Ochiai, J, Oczkowski, W, O'Donnell, MJ, Odyniec, A, Oh, K, Ohira, M, Okamoto, Y, Okpala, M, Okubo, S, Olah, L, Olavarria, V, Oleszek, J, Onat Demirci, N, Ondar, V, Ongun, G, Ooyama, K, Orosz, V, Ortiz, R, Osseby, G, Österlund-Tauriala, E, Ovesen, C, Ozcekic Demirhan, S, Ozdoba-Rot, J, Ozturk, S, Ozyurt, E, Pablo Grecco, M, Pablo Povedano, G, Paciaroni, M, Padiglioni, C, Pagola, J, Palasik, W, Panczel, G, Panos, L, Papadopoulos, G, Papadopoulou, E, Papagiannis, A, Papavasileiou, V, Papina, M, Pardo De Donlebun, JR, Parisi, V, Park, JM, Pasten, J, Patel, N, Pavlik, O, Pawelczyk, M, Peacock, WF, Pei, H, Peisker, T, Pena Sedna, LF, Penn, A, Pentek, S, Pepper, E, Pereira, L, Perera, K, Perez, Y, Perez, S, Perez Leguizamon, P, Pernicka, M, Perry, R, Persico, A, Pesant, Y, Peska, S, Peters, D, Peters, G, Pettigrew, L, Phan, T, Philippi, S, Phinney, T, Pico, F, Pidal, A, Piechowski-Jozwiak, B, Pieroni, A, Pineiro, S, Piras, V, Pizova, N, Polanco, J, Polin, M, Polyakov, A, Polychronopoulou, E, Polymeris, A, Popov, D, Poppe, A, Postorino, P, Pozzerese, C, Pradhan, M, Prats, L, Prazdnichkova, E, Prendl, B, Pretorius, M, Profice, P, Prokopenko, S, Pudov, E, Pujol Lereis, V, Punzo Bravo, G, Purroy, F, Qiu, J, Qu, X, Quenardelle, V, Quesada Garcia, H, Radrizzani, L, Radtke, A, Raffelsberger, T, Ramirez Moreno, JM, Ramos-Estebanez, C, Rani, A, Rapantova, P, Rashed, K, Rasheed Nihara, A, Rasmussen, J, Redondo Robles, L, Reif, M, Reiner, P, Rekova, P, Renu, A, Repetto, M, Reyes, P, Reyes Morales, S, Rha, JH, Ribeiro, J, Ricci, S, Richard, C, Rigual, R, Rinaldi, C, Riveira Rodriguez, C, Rizzato, B, Robinson, TG, Rocco, A, Rodrigues, M, Rodriguez, G, Rodriguez Campello, A, Rodriguez Lucci, F, Rodriguez Yanez, M, Roesler, C, Roffe, C, Roine, R, Roine, S, Roldan, A, Romana Pezzella, F, Romano, M, Roos, JS, Rosso, C, Rostrup Kruuse, C, Roth, Y, Roukens, R, Roveri, L, Rozanski, D, Rozniecki, J, Rozsa, C, Rudilosso, S, Ruiz Ares, G, Ruiz Franco, A, Rum, G, Ruuskanen, J, Rybinnik, I, Ryota, K, Saarinen, J, Saavedra, V, Sabben, C, Sabet, A, Sagris, D, Sahlas, J, Sakai, N, Salamanca, P, Salgado, P, Salig, S, Salletmayr, T, Salnikov, M, Samoshkina, O, Samson, Y, Sanak, D, Sànchez Cerón, M, Santalucia, P, Santamaria Cadavid, M, Santiago, P, Santo, G, Sanz Cuesta, B, Sargento, J, Sarraj, A, Sas, K, Sas, A, Satoshi, O, Satsoglou, S, Sattar, N, Savitz, S, Savopoulos, C, Saw, J, Sawicka, M, Sawyer, R, Scandura, T, Schillinger, N, Schindler, J, Schlachetzki, F, Schneider, I, Schuppner, R, Schurig, J, Schwarzbach, CJ, Sebejova, M, Seidel, G, Sekaran, L, Selcuk, D, Selvarajah, J, Semerano, A, Semjen, J, Semushina, D, Sen, S, Seok Park, M, Serena, J, Serhat Tokgoz, O, Serles, W, Serrano, F, Sevin, M, Seynaeve, L, Shah, S, Shamalov, N, Shang, T, Sharma, M, Sharrief, A, Shazam Hussain, M, Shchukin, I, Shen, W, Shepeleva, E, Shinsuke, I, Shmonin, A, Shoamanesh, A, Shuaib, A, Shulga, A, Sibolt, G, Sibon, I, Sicilia, I, Siebert, M, Sieczkowska, E, Sila, C, Silva, AA, Silva, D, Silva, P, Silva, Y, Silvestrini, M, Simony, Z, Simpkins, A, Singh, B, Sinha, D, Sipos, I, Skoda, O, Skowron, P, Skowronska, M, Sliwinska, B, Slonkova, J, Smolkin, A, Smyth, A, Sobolewski, P, Sobota, A, Sohn, SI, Soldatov, M, Solganov, I, Soloveva, L, Solovyeva, E, Sonntag, N, Soors, P, Sorgun, M, Soriano, C, Spence, D, Spengos, K, Sposato, L, Staaf, G, Stadler, K, Stakhovskaya, L, Stamatelopoulos, K, Steinert, S, Stetkarova, I, Stiehm, M, Stocker, R, Stoinski, J, Stoll, A, Stotts, G, Stumpp, A, Sucapane, P, Suenaga, T, Sun, X, Sundararajan, S, Sung Kim, J, Suzuki, H, Svaneborg, N, Szasz, G, Szczuchniak, W, Szczyrba, S, Szegedi, N, Szekely, A, Szewczyk, Z, Szilagyi, G, Szlufik, S, Szoboszlai, K, Szpisjak, L, Sztajzel, R, Sztriha, L, Ta Wil, SE, Taggeselle, J, Takamatsu, K, Takao, M, Taki, W, Takizawa, S, Talahma, M, Tamayo, A, Tan, J, Tanne, D, Tapanainen, A, Tapiola, T, Tarasiuk, J, Tatlisumak, T, Tayal, A, Tcvetkova, S, Teal, P, Tejada Garcia, J, Tejada Meza, H, Tenora, D, Terceno, M, Terentiou, A, Tezcan, S, Thaler, D, Thomson, A, Thouvenot, E, Tiainen, M, Timberg, I, Timsit, S, Tinchon, A, Tirschwell, D, Togay Isikay, C, Tokunaga, K, Tolino, M, Toloza, C, Tomelleri, G, Tomoyuki, K, Tomppo, LM, Tong, Z, Tong, L, Toni, D, Torres, J, Tossavainen, C, Toth, G, Tountopoulou, A, Touze, E, Tovar, M, Toyoda, K, Trillo, S, Trommer, A, Tropepi, D, Tryambake, D, Tu, H, Tuetuencue, S, Tumova, R, Tumpula, O, Turc, G, Tutaj, A, Tynkkynen, J, Uchiyama, S, Uchwat, U, Uhrinyakova, L, Ulku Acar, R, Uluduz Ugurlu, D, Urra, X, Urui, S, Usero Ruiz, M, Vaclavik, D, Vahedi, K, Valikovics, A, Valpas, J, Van Acker, P, Van Daele, W, Vanderschueren, G, Vanina Jure, L, Varela, R, Varga, Z, Varvat, J, Varvyanskaya, N, Vasco Salgado, A, Vasko, P, Vass, L, Vassilopoulou, S, Vastagh, I, Vazquez, P, Vecsei, L, Veltkamp, R, Venti, M, Verdugo, M, Verocai, V, Veronica Marroquin, M, Veronica Simonsini, C, Veverka, T, Vigl, M, Vila, A, Vilar, C, Villanueva Osorio, JA, Virta, J, Vitkova, E, Voglsperger, B, Volna, J, Von Weitzel-Mudersbach, PA, Vora, N, Voznyuk, I, Wach-Klink, A, Wacongne, A, Walters, D, Wang, Y, Wang, J, Wang, L, Wang, X, Wang, W, Wang, N, Wang, D, Wang, H, Warnack, W, Wartenberg, K, Waters, R, Waters, M, Webb, T, Weber, J, Weiss, G, Weissenborn, K, Weitz, JI, Weller, B, Wen, G, Weng, G, Werner, P, Werring, D, Wester, P, Whiteley, W, Whiting, R, Wijeratne, T, Willems, C, Wilson, L, Wilson, C, Winder, T, Windt, J, Winkler, A, Winska-Tereszkiewicz, A, Wisniewska, A, Wittayer, M, Wlodek, A, Wojnarowska-Arendt, A, Wolf, M, Wolff, V, Wolter, C, Wong, A, Wook Nah, H, Worthmann, H, Wu, W, Wu, S, Wunderlich, S, Wurzinger, H, Wyse, DG, Xiao, B, Xiaopeng, W, Ximenez-Carrillo, A, Xiong, L, Xiong, Y, Xiong, W, Xu, Y, Xu, J, Xu, Z, Yalo, B, Yamada, T, Yamasaki, M, Yang, L, Yang, Y, Yang, X, Yang, Q, Yang, B, Yang, J, Yasuhiro, I, Yee Lam, M, Yegappan, C, Yip, S, Ylikallio, E, Ylikotila, P, Yongwon Jin, A, Yoon, BW, Yoshida, Y, Yperzeele, L, Yuan, H, Yuasa, H, Zalewska, J, Zanferrari, C, Zapata, E, Zboznovits, D, Zelenka, I, Zhang, C, Zhang, B, Zhang, S, Zhang, M, Zhang, X, Zhang, J, Zhao, L, Zhirnova, O, Zhou, L, Zielinska-Turek, J, Zinchenko, I, Ziomek, M, Zitzmann, A, Zweifler, R, Zwiernik, J, Kasner, Scott E, Swaminathan, Balakumar, Lavados, Pablo, Sharma, Mukul, Muir, Keith, Veltkamp, Roland, Ameriso, Sebastian F, Endres, Matthias, Lutsep, Helmi, Messé, Steven R, Spence, J David, Nedeltechev, Krassen, Perera, Kanjana, Santo, Gustavo, Olavarria, Veronica, Lindgren, Arne, Bangdiwala, Shrikant, Shoamanesh, Ashkan, Berkowitz, Scott D, Mundl, Hardi, Connolly, Stuart J, and Hart, Robert G
Published: 2018
Full Text: View/download PDF

4. Light rings of five-dimensional geometries

Author: Bianchi, M., Consoli, D., Grillo, A., and Morales, J. F.
Published: 2021
Full Text: View/download PDF

5. Emergent/composite axions

Author: Anastasopoulos, P., Betzios, P., Bianchi, M., Consoli, D., and Kiritsis, E.
Published: 2019
Full Text: View/download PDF

6. The dark side of fuzzball geometries

Author: Bianchi, M., Consoli, D., Grillo, A., and Morales, J. F.
Published: 2019
Full Text: View/download PDF

7. Perturbative higher-derivative terms in N = 6 asymmetric orbifolds

Author: Bianchi, M, Bossard, G, and Consoli, D
Subjects: Settore FIS/02
Published: 2022

8. Previous infection and the risk of ischaemic stroke in Italy: the IN2 study

Author: Consoli, D., Vidale, S., Aguglia, U., Bassi, P., Cavallini, A., Galati, F., Guidetti, D., Marcello, N., Micieli, G., Pracucci, G., Rasura, M., Siniscalchi, A., Sterzi, R., Toni, D., and Inzitari, D.
Published: 2015
Full Text: View/download PDF

9. String (Gravi)photons, “Dark Brane Photons”, Holography and the Hypercharge Portal

Author: Anastasopoulos, P., primary, Bianchi, M., additional, Consoli, D., additional, and Kiritsis, E., additional
Published: 2021
Full Text: View/download PDF

10. Anticoagulation after Stroke in Patients with Atrial Fibrillation: To Bridge or Not with Low-Molecular-Weight Heparin?

Author: Altavilla, R. Caso, V. Bandini, F. Agnelli, G. Tsivgoulis, G. Yaghi, S. Furie, K.L. Tadi, P. Becattini, C. Zedde, M. Abdul-Rahim, A.H. Lees, K.R. Alberti, A. Venti, M. Acciarresi, M. D'Amore, C. Giulia Mosconi, M. Anna Cimini, L. Fusaro, J. Bovi, P. Carletti, M. Rigatelli, A. Cappellari, M. Putaala, J. Tomppo, L. Tatlisumak, T. Marcheselli, S. Pezzini, A. Poli, L. Padovani, A. Masotti, L. Vannucchi, V. Sohn, S.-I. Lorenzini, G. Tassi, R. Guideri, F. Acampa, M. Martini, G. Ntaios, G. Athanasakis, G. Makaritsis, K. Karagkiozi, E. Vadikolias, K. Liantinioti, C. Chondrogianni, M. Mumoli, N. Consoli, D. Galati, F. Sacco, S. Carolei, A. Tiseo, C. Corea, F. Ageno, W. Bellesini, M. Silvestrelli, G. Ciccone, A. Lanari, A. Scoditti, U. Denti, L. Mancuso, M. MacCarrone, M. Ulivi, L. Orlandi, G. Giannini, N. Gialdini, G. Tassinari, T. De Lodovici, M.L. Bono, G. Rueckert, C. Baldi, A. D'Anna, S. Toni, D. Letteri, F. Giuntini, M. Lotti, E.M. Flomin, Y. Pieroni, A. Kargiotis, O. Karapanayiotides, T. Monaco, S. Baronello, M.M. Csiba, L. Szabó, L. Chiti, A. Giorli, E. Del Sette, M. Imberti, D. Zabzuni, D. Doronin, B. Volodina, V. Michel, P. Vanacker, P. Barlinn, K. Pallesen, L.-P. Barlinn, J. Deleu, D. Melikyan, G. Ibrahim, F. Akhtar, N. Gourbali, V. Paciaroni, M.
Abstract: Background and Purpose-Bridging therapy with low-molecular-weight heparin reportedly leads to a worse outcome for acute cardioembolic stroke patients because of a higher incidence of intracerebral bleeding. However, this practice is common in clinical settings. This observational study aimed to compare (1) the clinical profiles of patients receiving and not receiving bridging therapy, (2) overall group outcomes, and (3) outcomes according to the type of anticoagulant prescribed. Methods-We analyzed data of patients from the prospective RAF and RAF-NOACs studies. The primary outcome was defined as the composite of ischemic stroke, transient ischemic attack, systemic embolism, symptomatic cerebral bleeding, and major extracerebral bleeding observed at 90 days after the acute stroke. Results-Of 1810 patients who initiated oral anticoagulant therapy, 371 (20%) underwent bridging therapy with full-dose low-molecular-weight heparin. Older age and the presence of leukoaraiosis were inversely correlated with the use of bridging therapy. Forty-two bridged patients (11.3%) reached the combined outcome versus 72 (5.0%) of the nonbridged patients (P=0.0001). At multivariable analysis, bridging therapy was associated with the composite end point (odds ratio, 2.3; 95% CI, 1.4-3.7; P
Published: 2019

11. Early recurrence in paroxysmal versus sustained atrial fibrillation in patients with acute ischaemic stroke

Author: Paciaroni, M. Angelini, F. Agnelli, G. Tsivgoulis, G. Furie, K.L. Tadi, P. Becattini, C. Falocci, N. Zedde, M. Abdul-Rahim, A.H. Lees, K.R. Alberti, A. Venti, M. Acciarresi, M. Altavilla, R. D’Amore, C. Mosconi, M.G. Cimini, L.A. Bovi, P. Carletti, M. Rigatelli, A. Cappellari, M. Putaala, J. Tomppo, L. Tatlisumak, T. Bandini, F. Marcheselli, S. Pezzini, A. Poli, L. Padovani, A. Masotti, L. Vannucchi, V. Sohn, S.-I. Lorenzini, G. Tassi, R. Guideri, F. Acampa, M. Martini, G. Ntaios, G. Karagkiozi, E. Athanasakis, G. Makaritsis, K. Vadikolias, K. Liantinioti, C. Chondrogianni, M. Mumoli, N. Consoli, D. Galati, F. Sacco, S. Carolei, A. Tiseo, C. Corea, F. Ageno, W. Bellesini, M. Silvestrelli, G. Ciccone, A. Scoditti, U. Denti, L. Mancuso, M. Maccarrone, M. Orlandi, G. Giannini, N. Gialdini, G. Tassinari, T. Lodovici, M.L.D. Bono, G. Rueckert, C. Baldi, A. Toni, D. Letteri, F. Giuntini, M. Lotti, E.M. Flomin, Y. Pieroni, A. Kargiotis, O. Karapanayiotides, T. Monaco, S. Baronello, M.M. Csiba, L. Szabó, L. Chiti, A. Giorli, E. Sette, M.D. Imberti, D. Zabzuni, D. Doronin, B. Volodina, V. Michel Pd-Mer, P. Vanacker, P. Barlinn, K. Pallesen, L.P. Kepplinger, J. Deleu, D. Melikyan, G. Ibrahim, F. Akhtar, N. Gourbali, V. Yaghi, S. Caso, V.
Subjects: cardiovascular system, macromolecular substances, cardiovascular diseases
Abstract: Background: The relationship between different patterns of atrial fibrillation and early recurrence after an acute ischaemic stroke is unclear. Purpose: In a prospective cohort study, we evaluated the rates of early ischaemic recurrence after an acute ischaemic stroke in patients with paroxysmal atrial fibrillation or sustained atrial fibrillation which included persistent and permanent atrial fibrillation. Methods: In patients with acute ischaemic stroke, atrial fibrillation was categorised as paroxysmal atrial fibrillation or sustained atrial fibrillation. Ischaemic recurrences were the composite of ischaemic stroke, transient ischaemic attack and symptomatic systemic embolism occurring within 90 days from acute index stroke. Results: A total of 2150 patients (1155 females, 53.7%) were enrolled: 930 (43.3%) had paroxysmal atrial fibrillation and 1220 (56.7%) sustained atrial fibrillation. During the 90-day follow-up, 111 ischaemic recurrences were observed in 107 patients: 31 in patients with paroxysmal atrial fibrillation (3.3%) and 76 with sustained atrial fibrillation (6.2%) (hazard ratio (HR) 1.86 (95% CI 1.24–2.81)). Patients with sustained atrial fibrillation were on average older, more likely to have diabetes mellitus, hypertension, history of stroke/ transient ischaemic attack, congestive heart failure, atrial enlargement, high baseline NIHSS-score and implanted pacemaker. After adjustment by Cox proportional hazard model, sustained atrial fibrillation was not associated with early ischaemic recurrences (adjusted HR 1.23 (95% CI 0.74–2.04)). Conclusions: After acute ischaemic stroke, patients with sustained atrial fibrillation had a higher rate of early ischaemic recurrence than patients with paroxysmal atrial fibrillation. After adjustment for relevant risk factors, sustained atrial fibrillation was not associated with a significantly higher risk of recurrence, thus suggesting that the risk profile associated with atrial fibrillation, rather than its pattern, is determinant for recurrence. © European Stroke Organisation 2018.
Published: 2019

12. Rivaroxaban for stroke prevention after embolic stroke of undetermined source

Author: Hart, Robert G, Sharma, Mukul, Mundl, Hardi, Kasner, Scott E, Bangdiwala, Shrikant I, Berkowitz, Scott D, Swaminathan, Balakumar, Lavados, Pablo, Wang, Yongjun, Wang, Yilong, Davalos, Antonio, Shamalov, Nikolay, Mikulik, Robert, Cunha, Luis, Lindgren, Arne, Arauz, Antonio, Lang, Wilfried, Czlonkowska, Anna, Eckstein, Jens, Gagliardi, Rubens J, Amarenco, Pierre, Ameriso, Sebastian F, Tatlisumak, Turgut, Veltkamp, Roland, Hankey, Graeme J, Toni, Danilo, Bereczki, Daniel, Uchiyama, Shinichiro, Ntaios, George, Yoon, Byung-Woo, Brouns, Raf, Endres, Matthias, Muir, Keith W, Bornstein, Natan, Ozturk, Serefnur, O'Donnell, Martin J, De Vries Basson, Matthys M, Pare, Guillaume, Pater, Calin, Kirsch, Bodo, Sheridan, Patrick, Peters, Gary, Weitz, Jeffrey I, Peacock, W Frank, Shoamanesh, Ashkan, Benavente, Oscar R, Joyner, Campbell, Themeles, Ellison, Connolly, Anderson DC, Stuart J., Demets, Dl, Kaste, M, Norrving, B, Wyse, Dg, Alet, M, Allende, G, Beinlich, A, Berrios, W, Bruera, G, Castro, D, Chialvo, L, Claverie, S, Contardo, L, Couto, J, Deganutto, R, Diaz, R, Dossi, D, Esnaola, M, Falco, M, Fernandez Pirrone, P, Ferrari, J, Firstenfeld, A, Galli Giqueauk, E, Gilli, M, Gonzalez, L, Gonzalez Toledo, M, Grecco, M, Halac, B, Hawkes, M, Ioli, P, Jure, L, Klein, F, Lepera, S, Lujan, S, Mackinnon, F, Marroquin, M, Martin, J, Parisi, V, Perez Leguizamon, P, Persi, G, Povedano, P, Povedano, G, Pujol Lereis, V, Radrizzani, L, Reich, E, Repetto, M, Rodriguez Lucci, F, Romano, M, Saredo, G, Schneider, M, Simonsini, C, Sumay, G, Thomson, A, Toledo, W, Torres, C, Vila, A, Abdul Rasheed, N, Anderson, C, Bailey, P, Blacker, D, Carcel, C, Clissold, B, Delcourt, C, Field, D, Gangadharan, S, Ghia, D, Kleinig, T, Leyden, J, Ly, J, Ma, H, Mackey, E, Mishra, S, Moey, A, Musuka, T, Pepper, E, Phan, T, Sabet, A, Saw, J, Singh, B, Tryambake, D, Tu, H, Wijeratne, T, Wong, A, Augustin, S, Esterbauer, M, Garnauf, M, Gasiorek, K, Gasser, S, Gaugg, M, Greisenegger, S, Harrasser, M, Heine, M, Huber, B, Joachim, B, Kapeller, P, Krebs, S, Kreuzpointer, R, Kunzmann, J, Lechner, H, Lohninger, B, Luschin, G, Macher, S, Marko, M, Matosevic, B, Mayr, A, Mismas, A, Mitrovic, N, Mutzenbach, J, Oberndorfer, S, Obmann, S, Raffelsberger, T, Roesler, C, Salletmayr, T, Serles, W, Stadler, K, Tinchon, A, Tolino, M, Verocai, V, Vigl, M, Voglsperger, B, Weber, J, Werner, P, Windt, J, Winkler, A, Wurzinger, H, Zelenka, I, Cras, P, Crols, R, De Keyser, J, De Klippel, N, De Pauw, A, De Smedt, A, Dhollander, I, Hermans, S, Ligot, N, Maqueda, V, Maqueda Maqueda, V, Naeije, G, Seynaeve, L, Soors, P, Van Daele, W, Vanacker, P, Vanderschueren, G, Willems, C, Yperzeele, L, Avelar, W, Bacellar, A, Batista, C, Bazan, R, Braga, G, Cardoso, F, Dagnino, M, Fabio, S, Ferreira Junior, G, Freitas, G, Friedrich, M, Gomes Neto, A, Guarda, S, Katsurayama, M, Machado, M, Martins, S, Meira, F, Minelli, C, Morais, R, Moro, C, Neto, O, Polin, M, Silva, D, Weiss, G, Basile, V, Beaudry, M, Berlingieri, J, Blacquiere, D, Buck, B, Chan, R, Coutts, S, Das, S, Desai, J, Ehrensperger, E, Field, T, Gladstone, D, Hachinski, V, Hassan, A, Hegedus, J, Hill, M, Jin, A, Khaw, A, Mackey, A, Maclean, G, Mandzia, J, Mann, S, Mehdiratta, M, Murphy, C, Ng, K, Oczkowski, W, Penn, A, Perera, K, Perez, Y, Pesant, Y, Phillips, S, Poppe, A, Sahlas, J, Shuaib, A, Spence, D, Sposato, L, Stotts, G, Tamayo, A, Teal, P, Wilson, L, Winder, T, Yegappan, C, Yip, S, Andreu, D, Araya, P, Bustamante, G, Figueroa, C, Gasic, K, Herrero, D, Matamala, G, Munoz, S, Olavarria, V, Pasten, J, Polanco, J, Reyes, P, Roldan, A, Salamanca, P, Silva, P, Toloza, C, Verdugo, M, Cai, K, Che, C, Chen, J, Chen, Z, Chen, T, Chen, H, Chen, X, Chen, B, Chen, G, Chen, L, Chu, F, Cui, L, Dai, C, Ding, N, Ding, J, Du, P, Du, J, Fang, L, Feng, J, Gao, Y, Geng, J, Guan, J, Hao, L, Huang, D, Huang, H, Jin, X, Jing, P, Ke, K, Li, G, Li, M, Li, S, Li, J, Liang, Z, Lin, H, Liu, K, Liu, X, Lu, Z, Ma, C, Pei, H, Qiu, J, Qu, X, Shen, W, Sun, X, Tian, J, Tong, L, Tong, Z, Wang, J, Wang, L, Wang, X, Wang, W, Wang, N, Wang, D, Wang, H, Wen, G, Weng, G, Wu, W, Wu, S, Xiao, B, Xiaopeng, W, Xiong, L, Xiong, Y, Xu, Y, Xu, J, Xu, Z, Yang, L, Yang, Y, Yang, X, Yang, J, Yang, Q, Yang, B, Zhang, C, Zhang, B, Zhang, Y, Zhang, S, Zhang, M, Zhang, X, Zhang, J, Zhao, L, Zhou, L, Bar, M, Barteys, M, Bartolottiova, T, Carek, M, Ferencova, K, Fiksa, J, Gallo, J, Goldemund, D, Hanouskova, L, Herzig, R, Hon, P, Jankovych, J, Jura, R, Kadlcikova, J, Kemlink, D, Kopecky, S, Krajickova, D, Kral, M, Krejci, V, Pavlik, O, Peisker, T, Pernicka, M, Peska, S, Rapantova, P, Reif, M, Rekova, P, Sanak, D, Sebejova, M, Skoda, O, Slonkova, J, Stetkarova, I, Tenora, D, Tumova, R, Vaclavik, D, Vasko, P, Veverka, T, Vitkova, E, Volna, J, Andersen, G, Christensen, H, Christensen, T, Damgaard, D, Iversen, H, Krarup Hansen, C, Kruuse, C, Martinussen, M, Modrau, B, Murtuzova, A, Ovesen, C, Papina, M, Svaneborg, N, Von Weitzel-Mudersbach, P, Curtze, S, Fanta, S, Huhtakangas, J, Keskinarkaus, I, Kivioja, R, Koivu, M, Korpela, J, Larjo, T, Linna, M, Marinkovic, I, Martinez-Majander, N, Nieminen, T, Nikkanen, M, Numminen, H, Ortiz, R, Österlund-Tauriala, E, Roine, R, Roine, S, Ruuskanen, J, Saarinen, J, Shulga, A, Sibolt, G, Tapanainen, A, Tapiola, T, Tiainen, M, Tomppo, L, Tumpula, O, Tuomainen, P, Tynkkynen, J, Vainikka, S, Valpas, J, Virta, J, Ylikallio, E, Ylikotila, P, Accassat, S, Aniculaesei, A, Baronnet, F, Bejot, Y, Bindila, D, Birchenall, J, Blanc-Labarre, C, Bodiguel, E, Bouly, S, Cabrejo, L, Calvet, D, Corlobe, A, Crozier, S, Delpont, B, Deltour, S, Diaconu, M, Domigo, V, Epinat, M, Ferreira, A, Fisselier, M, Garnier, P, Gimenez, L, Gueguen, A, Guidoux, C, Guillon, B, Guiraudg, V, Hervieu-Begue, M, Hobeanu, M, Khoumri, C, Lamy, C, Lauer, V, Le Bouc, R, Lecouturier, K, Leder, S, Leger, A, Macian-Montoro, F, Meseguer, E, Morar-Precup, D, Morvan, T, Morvan, E, Obadia, M, Osseby, G, Philippi, S, Pico, F, Quenardelle, V, Reiner, P, Rigual, R, Rosso, C, Sabben, C, Samson, Y, Sevin, M, Sibon, I, Thouvenot, E, Timsit, S, Touze, E, Turc, G, Vahedi, K, Varvat, J, Wacongne, A, Wolff, V, Yalo, B, Zinchenko, I, Bagelmann, H, Bardutzky, J, Barlinn, J, Bathe-Peters, R, Berrouschot, J, Dietzel, J, Ehrlich, S, Fatar, M, Filipov, A, Fluri, F, Gabriel, M, Geran, R, Gliem, M, Graf, S, Griebe, M, Grosse, G, Haeusler, K, Harmel, P, Held, V, Hellwig, S, Henkner, J, Hieber, M, Hoyer, C, Jander, S, Keilitz, J, Kellner, J, Knecht, S, Koch, M, Koehler, L, Kucken, D, Kusnick, G, Lambeck, J, Lee, J, Leisse, I, Lubke-Detring, S, Machetanz, J, Mensch, A, Meyer, N, Molis, A, Mueller, T, Muhl, C, Nave, A, Radtke, A, Roth, Y, Roukens, R, Schlachetzki, F, Schneider, I, Schuppner, R, Schurig, J, Schwarzbach, C, Seidel, G, Sonntag, N, Steinert, S, Stoll, A, Stumpp, A, Taggeselle, J, Trommer, A, Tuetuencue, S, Wartenberg, K, Weissenborn, K, Wittayer, M, Wolf, M, Wolter, C, Worthmann, H, Wunderlich, S, Zitzmann, A, Anagnostou, E, Brokalaki, C, Hatzitolios, A, Kakaletsis, N, Kanellos, I, Kei, A, Korompoki, E, Koutroubi, A, Liamis, G, Makaritsis, K, Manios, E, Michas, F, Milionis, H, Papadopoulos, G, Papadopoulou, E, Papagiannis, A, Polychronopoulou, E, Sagris, D, Satsoglou, S, Savopoulos, C, Solganov, I, Spengos, K, Stamatelopoulos, K, Terentiou, A, Tountopoulou, A, Vassilopoulou, S, Amjad, A, Balazs, A, Bankuti, Z, Bicsak, T, Borcsik, L, Csanyi, A, Csiba, L, Csontos, K, Csuha, R, Czurko, M, Danku, V, Dioszeghy, P, Faust, K, Fazekas, F, Gerocs, Z, Gottschal, M, Gyuker, N, Hajas, A, Horvath, L, Horvath, M, Iljicsov, A, Jakab, K, Javor, L, Kakuk, I, Karasz, O, Kasa, K, Kasza, J, Kerekgyarto, M, Klivenyi, P, Kovacs, K, Kovacs, T, Kovacs, H, Lajos, B, Lovasz, R, Magyar, T, Matoltsy, A, May, Z, Molnar, S, Monosi, C, Motko, T, Nemeth, R, Nemeth, L, Nikl, J, Olah, L, Orosz, V, Panczel, G, Pentek, S, Prendl, B, Rozsa, C, Rum, G, Sas, K, Sas, A, Semjen, J, Simony, Z, Sipos, I, Szabo, K, Szasz, G, Szegedi, N, Szekely, A, Szilagyi, G, Szoboszlai, K, Szpisjak, L, Toth, G, Uhrinyakova, L, Valikovics, A, Varga, Z, Vass, L, Vastagh, I, Vecsei, L, Zboznovits, D, Coveney, S, Horgan, G, Kelly, P, Murphy, S, Smyth, A, Waters, R, Abu Ahmad, F, Bloch, S, Dorodnicov, E, Hallevi, H, Haratz, S, Horev, A, Kolianov, V, Leker, R, Mahagney, A, Marzelik, O, Rephaeli, G, Tanne, D, Weller, B, Acciarresi, M, Adami, A, Agostoni, E, Alemseged, F, Altavilla, R, Angelocola, S, Anticoli, S, Berardi, V, Bravi, M, Candeloro, E, Cappellari, M, Carletti, M, Caruso, P, Castellini, P, Cavallini, A, Cenciarelli, S, Cerrone, P, Condurso, R, Consoli, D, Danese, A, Della Marca, G, Denaro, M, Di Mascio, M, Diomedi, M, Distefano, M, Frisullo, G, Furlanis, G, Galati, F, Gallina, A, Gallinella, E, Giannandrea, D, Giatsidis, F, Greco, L, Impellizzeri, M, Landolfi, A, Lanfranconi, S, Latte, L, Lembo, G, Longoni, M, Marando, C, Marini, C, Marsili, E, Mastrocola, S, Mazzoli, T, Melis, M, Micheletti, N, Moller, J, Monzani, V, Naccarato, M, Paciaroni, M, Padiglioni, C, Persico, A, Pezzella, F, Pieroni, A, Piras, V, Postorino, P, Pozzerese, C, Profice, P, Ricci, S, Rinaldi, C, Rizzato, B, Rocco, A, Roveri, L, Santalucia, P, Semerano, A, Sicilia, I, Silvestrini, M, Sucapane, P, Tomelleri, G, Tropepi, D, Venti, M, Amino, T, Chin, M, Deguchi, I, Fujigasaki, H, Fukuyama, K, Haraguchi, K, Hasegawa, Y, Hattori, M, Hayashi, T, Hirose, M, Honma, Y, Igarashi, S, Irie, S, Itabashi, R, Ito, Y, Kamata, T, Kaneko, C, Kawanishi, M, Kimura, R, Kitagawa, K, Kobayashi, Y, Kondo, T, Kuwashiro, T, Matsumoto, S, Miyake, H, Nagakane, Y, Nishino, S, Nishiyama, Y, Nogawa, S, Ochiai, J, Ohira, M, Okamoto, Y, Okubo, S, Okuda, S, Ooyama, K, Sakai, N, Suenaga, T, Suzuki, H, Takamatsu, K, Takao, M, Taki, W, Takizawa, S, Tokunaga, K, Toyoda, K, Urui, S, Yamada, T, Yamasaki, M, Yoshida, Y, Yuasa, H, Bae, H, Cha, J, Chang, D, Chung, C, Heo, J, Hong, K, Kim, J, Lee, B, Nah, H, Oh, K, Park, M, Park, J, Rha, J, Sohn, S, Amaya Sanchez, L, Arauz Gongora, A, Cantu Brito, C, Chiquete Anaya, E, Felipe Amaya, P, Fernandez Vera, J, Garcia Lopez, R, Gien Lopez, J, Gongora-Rivera, J, Hernandez, J, Leal Cantu, R, Lopez Garza, N, Medina Pech, C, Mendez, B, Pena Sedna, L, Reyes Morales, S, Ruiz Franco, A, Serrano, F, Tovar, M, Uribe, R, Bak, Z, Baranowska, A, Bilik, M, Blazejewska-Hyzorek, B, Brola, W, Brzoska-Mizgalska, J, Buksinska-Lisik, M, Chorazy, M, Czerska, M, Czuryszkiewicz, M, Dalek, G, Dylewicz, L, Fiszer, U, Fraczek, A, Friedman, A, Fryze, W, Gasecki, D, Gębura, K, Geremek, M, Glabinski, A, Gluszkiewicz, M, Goździk, I, Grzesik, M, Jasek, L, Kaczorowska, B, Kalinowska, K, Kaminska, K, Kapica-Topczewska, K, Karlinski, M, Kobayashi, A, Kosarz-Lanczek, K, Kowalczyk, K, Kowalska, M, Kraska, J, Krzyzanowska, M, Kulakowska, A, Kurkowska-Jastrzebska, I, Lasek-Bal, A, Litwin, T, Morton, M, Myśliwy, W, Nosek, K, Nowak, B, Nowakowska-Śledź, E, Odyniec, A, Oleszek, J, Ozdoba-Rot, J, Palasik, W, Pawelczyk, M, Rozanski, D, Rozniecki, J, Sawicka, M, Sieczkowska, E, Skowron, P, Skowronska, M, Sliwinska, B, Sobolewski, P, Sobota, A, Stoiński, J, Szczuchniak, W, Szczyrba, S, Szewczyk, Z, Szlufik, S, Tarasiuk, J, Tutaj, A, Uchwat, U, Wach-Klink, A, Winska-Tereszkiewicz, A, Wisniewska, A, Włodek, A, Wojnarowska-Arendt, A, Zalewska, J, Zielinska-Turek, J, Ziomek, M, Zwiernik, J, Abreu, P, E Silva A, Amaral, Azevedo, E, Barroso, C, Calejo, M, Campillo, J, Campos Costa, E, Coelho, J, Correia, M, Correia, C, Gregorio, T, Lopes, D, Machado, C, Mendonca, T, Pereira, L, Pidal, A, Pineiro, S, Pinto, A, Ribeiro, J, Rodrigues, M, Salgado, P, Salgado, A, Santo, G, Sargento, J, Varela, R, Abroskina, M, Badalyan, K, Balueva, T, Barulin, A, Bazhenova, O, Belkin, A, Bogdanov, E, Daineko, A, Druzenko, I, Fedin, A, Fidler, M, Gogoleva, E, Golikov, K, Gonysheva, Y, Greshnova, I, Guryanova, N, Gusev, V, Kashaeva, E, Kaygorodtseva, S, Khairutdinova, D, Kholopov, M, Kirpicheva, S, Koltsov, I, Konkov, I, Kurenkova, N, Kurtenkova, N, Kurushina, O, Kustova, M, Lagutenko, M, Lenskaya, L, Lupinogina, L, Lvova, A, Melnikova, E, Meshkova, K, Morozova, E, Mozhejko, E, Nikoforova, M, Obrezan, A, Ondar, V, Pizova, N, Polyakov, A, Popov, D, Prazdnichkova, E, Prokopenko, S, Pudov, E, Salnikov, M, Samoshkina, O, Semushina, D, Shchukin, I, Shepeleva, E, Shmonin, A, Smolkin, A, Soldatov, M, Soloveva, L, Solovyeva, E, Stakhovskaya, L, Tcvetkova, S, Varvyanskaya, N, Voznyuk, I, Zhirnova, O, Ahmed, F, Basson, M, Engelbrecht, J, Hobson, B, Jansen, J, Nel, J, Nell, H, Njovane, X, Pretorius, M, Roos, J, Salig, S, Siebert, M, Amaro, S, Arenillas Lara, J, Arias Rivas, S, Baez Martinez, E, Bas, M, Bashir, S, Bragado, I, Cajaraville, S, Camps, P, Cardona Portela, P, Casado-Naranjo, I, Castellanos, M, Cayuela Caudevilla, N, Chamorro, A, Constantino Silva, A, Cortijo Garcia, E, De La Torre, J, De Torres, R, Diaz Otero, F, Diez-Tejedor, E, Escribano, B, Escudero, I, Fernandez, M, Font, M, Fortea, G, Freijo, M, Fuentes Gimeno, B, Gamero, M, Garcia, J, Garcia Pastor, A, Garcia Sanchez, S, Geniz Clavijo, M, Gil Nunez, A, Giralt, E, Gomez-Choco, M, Gomis, M, Gutiérrez, R, Iglesias Mohedano, A, Lago, A, Lara Lezama, L, Lara Rodriguez, B, Llull, L, Lopez Fernandez, M, Lorenzo, A, Maestre-Moreno, J, Marta Moreno, J, Marti-Fabregas, J, Martínez Sánchez, P, Mauri Cabdevila, G, Mengual Chirifie, J, Molina, C, Molina, J, Moniche, F, Morales, L, Morales, A, Nombela, F, Núñez, F, Pagola, J, Perez, S, Portilla, J, Prats, L, Purroy, F, Quesada Garcia, H, Ramirez Moreno, J, Redondo Robles, L, Renu, A, Riveira Rodriguez, C, Roa, A, Rodriguez Campello, A, Rodriguez Pardo De Donlebun, J, Rodriguez Yanez, M, Rudilosso, S, Ruiz Ares, G, Sànchez Cerón, M, Santamaria Cadavid, M, Sanz Cuesta, B, Serena, J, Silva, Y, Soriano Soriano, C, Tejada Garcia, J, Tejada Meza, H, Tembl, J, Terceno, M, Trillo, S, Urra, X, Usero Ruiz, M, Vazquez, P, Vilar, C, Villanueva Osorio, J, Ximenez-Carrillo, A, Zapata, E, Esbjornsson, M, Karlsson, J, Kremer, C, Kuris, A, Staaf, G, Stiehm, M, Timberg, I, Tossavainen, C, Wester, P, Arnold, M, Baumgartner, P, Beer, J, Bicker, H, Boos, L, Cereda, C, Chaloulos-Iakovidis, P, Christian, L, Engelter, S, Fisch, L, Fischer, U, Frey, S, Frick, M, Hauk, M, Hoffmann, M, Kahles, T, Manno, C, Medlin, F, Mircea, D, Nedeltchev, K, Panos, L, Polymeris, A, Schillinger, N, Stocker, R, Sztajzel, R, Alaydin, H, Batur Caglayan, H, Colakoglu, S, Demirci, N, Duman, T, Eren, F, Gokce, M, Inanc, Y, Nazliel, B, Ongun, G, Ozcekic Demirhan, S, Ozyurt, E, Selcuk, D, Sorgun, M, Tezcan, S, Togay Isikay, C, Tokgoz, O, Ulku Acar, R, Uluduz Ugurlu, D, Abdul-Saheb, M, Ahmad, N, Ali, A, Alwis, L, Balogun, I, Bathula, R, Behnam, Y, Bhandari, M, Bhargavah, M, Black, T, Blank, C, Bruce, D, Burn, M, Canepa, C, Chakrabarti, A, Chandrasena, D, Chembala, J, Cheripelli, B, Clarke, R, Cohen, D, Collas, D, Constantin, C, Dani, K, Del Giudice, A, Dennis, M, Devine, J, Dima, S, Doubal, F, Duodu, Y, Dutta, D, El Ta Wil, S, Elyas, S, Evans, N, Eveson, D, Fotherby, K, France, E, Furnace, J, Grabowski, S, Gunathilagan, G, Gutierrez, R, Guyler, P, Hargroves, D, Harkness, K, Harvey, M, Hayhoe, H, Hicken, L, Hussain, M, Kelly, S, Lam, M, Lindert, R, Louw, S, Luder, R, Macleod, M, Majid, A, Mangion, D, Markova, S, Markus, H, Marsh, R, Mcarthur, K, Menon, N, Metcalf, K, Minhas, J, Minns, M, Mistri, A, Moreton, F, Mpelembue, M, Muddegowda, G, Mudhar, O, Musarrat, K, Myint, M, Natarajan, I, Naylor, D, Ngeh, J, Papavasileiou, V, Perry, R, Piechowski-Jozwiak, B, Pradhan, M, Rani, A, Rashed, K, Robinson, T, Roffe, C, Saksena, R, Sattar, N, Sekaran, L, Selvarajah, J, Shah, S, Sinha, D, Sivakumar, R, Sztriha, L, Walters, D, Webb, T, Werring, D, Whiteley, W, Whiting, R, Abdelhamid, N, Abdul Rahman, D, Amin, H, Androulakis, M, Babikian, V, Baker, M, Barker Trejo, S, Benjamin, A, Birnbaum, L, Burke, J, Chen, S, Clark, W, Coull, B, De Havenon, A, Dearborn, J, Degeorgia, M, Essa, B, Fares, M, Favate, A, Furlan, A, Gebreyohanns, M, Goddeau, R, Green, D, Greer, D, Haralur Sreekantaiah, Y, Hasan, R, Hedna, V, Henninger, N, Holmstedt, C, Ishida, K, Jagolino, A, Johnson, M, Jun-Oconnell, A, Kaur, S, Khanna, A, Kirshner, H, Kittner, S, Kleindorfer, D, Leira, E, Loomis, C, Lord, A, Lowenkopf, T, Lutsep, H, Magadan, A, Majjhoo, A, Maud, A, Mayasi, Y, Mccullough, L, Mckinney, J, Mehta, S, Mehta, D, Mehta, B, Messe, S, Miller, B, Milling, T, Moonis, M, Navaratnam, D, Okpala, M, Patel, N, Pettigrew, L, Phinney, T, Ramos-Estebanez, C, Rasmussen, J, Rodriguez, G, Rybinnik, I, Santiago, P, Sarraj, A, Savitz, S, Sawyer, R, Scandura, T, Schindler, J, Sen, S, Shang, T, Sharrief, A, Sila, C, Simpkins, A, Sundararajan, S, Talahma, M, Tayal, A, Thaler, D, Tirschwell, D, Torres, J, Vora, N, Warnack, W, Waters, M, Wilson, C, Xiong, W, Zweifler, R, Zanferrari, C., St Marys Development Trust, Servicio de Neurologia (SANTIAGO - Neurologie), Universidad del Desarrollo, Department of Neurology (Dep Neuro - BEIJING), Tiantan Hospital, Neurology department, Universidade de Coimbra [Coimbra], Department of Internal Medicine, University Hospital Basel [Basel], Laboratoire de Recherche Vasculaire Translationnelle (LVTS (UMR_S_1148 / U1148)), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Neurological Sciences, Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome], Department of Neurology, Seoul National University Hospital, Institute of Neurosciences and Psychology [Glasgow], University of Glasgow, Neurology Department, Ichilov Medical Center, CIC Brest, Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital de la Cavale Blanche, Yperzeele, Laetitia, NAVIGATE ESUS Investigators, and Selçuk Üniversitesi
Subjects: Stroke/etiology, Male, [SDV]Life Sciences [q-bio], Kaplan-Meier Estimate, 030204 cardiovascular system & hematology, Brain Ischemia, Brain ischemia, 0302 clinical medicine, DESIGN, Rivaroxaban, Hemorrhage/chemically induced, Secondary Prevention, Medicine, Factor Xa Inhibitors/adverse effects, Stroke, Rivaroxaban/adverse effects, ComputingMilieux_MISCELLANEOUS, 11 Medical and Health Sciences, Aspirin, Atrial fibrillation, General Medicine, FORAMEN OVALE CLOSURE, Middle Aged, TRIALS, Intracranial Embolism, SAFETY, Aged, Factor Xa Inhibitors, Female, Hemorrhage, Humans, Platelet Aggregation Inhibitors, Medicine (all), Cardiology, Foramen ovale closure, Platelet aggregation inhibitor, Settore MED/26 - Neurologia, Life Sciences & Biomedicine, medicine.drug, medicine.medical_specialty, Platelet Aggregation Inhibitors/adverse effects, ANTITHROMBOTIC THERAPY, Aspirin/adverse effects, WARFARIN, 03 medical and health sciences, Secondary Prevention/methods, Medicine, General & Internal, Internal medicine, Intracranial Embolism/drug therapy, General & Internal Medicine, NAVIGATE ESUS Investigators, METAANALYSIS, Science & Technology, CRYPTOGENIC STROKE, business.industry, Warfarin, medicine.disease, EFFICACY, ATRIAL-FIBRILLATION, Human medicine, business, Brain Ischemia/prevention & control, 030217 neurology & neurosurgery, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: WOS: 000434263000007, PubMed: 29766772, BACKGROUND Embolic strokes of undetermined source represent 20% of ischemic strokes and are associated with a high rate of recurrence. Anticoagulant treatment with rivaroxaban, an oral factor Xa inhibitor, may result in a lower risk of recurrent stroke than aspirin. METHODS We compared the efficacy and safety of rivaroxaban (at a daily dose of 15 mg) with aspirin (at a daily dose of 100 mg) for the prevention of recurrent stroke in patients with recent ischemic stroke that was presumed to be from cerebral embolism but without arterial stenosis, lacune, or an identified cardioembolic source. The primary efficacy outcome was the first recurrence of ischemic or hemorrhagic stroke or systemic embolism in a time-to-event analysis; the primary safety outcome was the rate of major bleeding. RESULTS A total of 7213 participants were enrolled at 459 sites; 3609 patients were randomly assigned to receive rivaroxaban and 3604 to receive aspirin. Patients had been followed for a median of 11 months when the trial was terminated early because of a lack of benefit with regard to stroke risk and because of bleeding associated with rivaroxaban. The primary efficacy outcome occurred in 172 patients in the rivaroxaban group (annualized rate, 5.1%) and in 160 in the aspirin group (annualized rate, 4.8%) (hazard ratio, 1.07; 95% confidence interval [CI], 0.87 to 1.33; P=0.52). Recurrent ischemic stroke occurred in 158 patients in the rivaroxaban group (annualized rate, 4.7%) and in 156 in the aspirin group (annualized rate, 4.7%). Major bleeding occurred in 62 patients in the rivaroxaban group (annualized rate, 1.8%) and in 23 in the aspirin group (annualized rate, 0.7%) (hazard ratio, 2.72; 95% CI, 1.68 to 4.39; P, BayerBayer AG; Janssen Research and Development, Supported by Bayer and Janssen Research and Development.
Published: 2018

13. Hemorrhagic transformation in patients with acute ischemic stroke and atrial fibrillation: Time to initiation of oral anticoagulant therapy and outcomes

Author: Paciaroni, M. Bandini, F. Agnelli, G. Tsivgoulis, G. Yaghi, S. Furie, K.L. Tadi, P. Becattini, C. Zedde, M. Abdul-Rahim, A.H. Lees, K.R. Alberti, A. Venti, M. Acciarresi, M. D’Amore, C. Mosconi, M.G. Cimini, L.A. Altavilla, R. Volpi, G. Bovi, P. Carletti, M. Rigatelli, A. Cappellari, M. Putaala, J. Tomppo, L. Tatlisumak, T. Marcheselli, S. Pezzini, A. Poli, L. Padovani, A. Masotti, L. Vannucchi, V. Sohn, S.-I. Lorenzini, G. Tassi, R. Guideri, F. Acampa, M. Martini, G. Ntaios, G. Athanasakis, G. Makaritsis, K. Karagkiozi, E. Vadikolias, K. Liantinioti, C. Chondrogianni, M. Mumoli, N. Consoli, D. Galati, F. Sacco, S. Carolei, A. Tiseo, C. Corea, F. Ageno, W. Bellesini, M. Colombo, G. Silvestrelli, G. Ciccone, A. Lanari, A. Scoditti, U. Denti, L. Mancuso, M. Maccarrone, M. Ulivi, L. Orlandi, G. Giannini, N. Gialdini, G. Tassinari, T. De Lodovici, M.L. Bono, G. Rueckert, C. Baldi, A. D'Anna, S. Toni, D. Letteri, F. Giuntini, M. Lotti, E.M. Flomin, Y. Pieroni, A. Kargiotis, O. Karapanayiotides, T. Monaco, S. Baronello, M.M. Csiba, L. Szabó, L. Chiti, A. Giorli, E. Del Sette, M. Imberti, D. Zabzuni, D. Doronin, B. Volodina, V. Michel, P. Vanacker, P. Barlinn, K. Pallesen, L.-P. Barlinn, J. Deleu, D. Melikyan, G. Ibrahim, F. Akhtar, N. Gourbali, V. Caso, V.
Abstract: Background—In patients with acute ischemic stroke and atrial fibrillation, early anticoagulation prevents ischemic recurrence but with the risk of hemorrhagic transformation (HT). The aims of this study were to evaluate in consecutive patients with acute stroke and atrial fibrillation (1) the incidence of early HT, (2) the time to initiation of anticoagulation in patients with HT, (3) the association of HT with ischemic recurrences, and (4) the association of HT with clinical outcome at 90 days. Methods and Results—HT was diagnosed by a second brain computed tomographic scan performed 24 to 72 hours after stroke onset. The incidence of ischemic recurrences as well as mortality or disability (modified Rankin Scale scores >2) were evaluated at 90 days. Ischemic recurrences were the composite of ischemic stroke, transient ischemic attack, or systemic embolism. Among the 2183 patients included in the study, 241 (11.0%) had HT. Patients with and without HT initiated anticoagulant therapy after a mean 23.3 and 11.6 days, respectively, from index stroke. At 90 days, 4.6% (95% confidence interval, 2.3-8.0) of the patients with HT had ischemic recurrences compared with 4.9% (95% confidence interval, 4.0-6.0) of those without HT; 53.1% of patients with HT were deceased or disabled compared with 35.8% of those without HT. On multivariable analysis, HT was associated with mortality or disability (odds ratio, 1.71; 95% confidence interval, 1.24-2.35). Conclusions—In patients with HT, anticoagulation was initiated about 12 days later than patients without HT. This delay was not associated with increased detection of ischemic recurrence. HT was associated with increased mortality or disability. © 2018 The Authors.
Published: 2018

14. Intravenous thrombolysis in stroke mimics: results from the SITS International Stroke Thrombolysis Register

Author: Keselman, B., primary, Cooray, C., additional, Vanhooren, G., additional, Bassi, P., additional, Consoli, D., additional, Nichelli, P., additional, Peeters, A., additional, Sanak, D., additional, Zini, A., additional, Wahlgren, N., additional, Ahmed, N., additional, and Mazya, M. V., additional
Published: 2019
Full Text: View/download PDF

15. Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial

Author: Kasner, Scott E, primary, Swaminathan, Balakumar, additional, Lavados, Pablo, additional, Sharma, Mukul, additional, Muir, Keith, additional, Veltkamp, Roland, additional, Ameriso, Sebastian F, additional, Endres, Matthias, additional, Lutsep, Helmi, additional, Messé, Steven R, additional, Spence, J David, additional, Nedeltechev, Krassen, additional, Perera, Kanjana, additional, Santo, Gustavo, additional, Olavarria, Veronica, additional, Lindgren, Arne, additional, Bangdiwala, Shrikant, additional, Shoamanesh, Ashkan, additional, Berkowitz, Scott D, additional, Mundl, Hardi, additional, Connolly, Stuart J, additional, Hart, Robert G, additional, Abdelhamid, N, additional, Abdul Rahman, D, additional, Abdul-Saheb, M, additional, Abreu, P, additional, Abroskina, M, additional, Abu Ahmad, F, additional, Accassat, S, additional, Acciaresi, M, additional, Adami, A, additional, Ahmad, N, additional, Ahmed, F, additional, Alberto Hawkes, M, additional, Alemseged, F, additional, Ali, A, additional, Altavilla, R, additional, Alwis, L, additional, Amarenco, P, additional, Amaro, S, additional, Amaya Sanchez, LE, additional, Amelia Pinto, A, additional, Ameriso, SF, additional, Amin, H, additional, Amino, T, additional, Amjad, AK, additional, Anagnostou, E, additional, Andersen, G, additional, Anderson, C, additional, Anderson, DC, additional, Andrea Falco, M, additional, Andres Mackinnon, F, additional, Andreu, D, additional, Androulakis, M, additional, Angel Gamero, M, additional, Angel Saredo, G, additional, Angeles Diaz, R, additional, Angels Font, M, additional, Anticoli, S, additional, Arauz, A, additional, Arauz Gongora, AA, additional, Araya, P, additional, Arenillas Lara, JF, additional, Arias Rivas, S, additional, Arnold, M, additional, Augustin, S, additional, Avelar, W, additional, Azevedo, E, additional, Babikian, V, additional, Bacellar, A, additional, Badalyan, K, additional, Bae, HJ, additional, Baez Martinez, EM, additional, Bagelmann, H, additional, Bailey, P, additional, Bak, Z, additional, Baker, M, additional, Balazs, A, additional, Baldaranov, D, additional, Balogun, I, additional, Balueva, T, additional, Bankuti, Z, additional, Bar, M, additional, Baranowska, A, additional, Bardutzky, J, additional, Barker Trejo, S, additional, Barlinn, J, additional, Baronnet, F, additional, Barroso, C, additional, Barteys, M, additional, Bartolottiova, T, additional, Barulin, A, additional, Bas, M, additional, Bashir, S, additional, Basile, V, additional, Bathe-Peters, R, additional, Bathula, R, additional, Batista, C, additional, Batur Caglayan, H, additional, Baumgartner, P, additional, Bazan, R, additional, Bazhenova, O, additional, Beaudry, M, additional, Beer, J, additional, Behnam, Y, additional, Beilei, C, additional, Beinlich, A, additional, Bejot, Y, additional, Belkin, A, additional, Benavente, OR, additional, Benjamin, A, additional, Berardi, V, additional, Bereczki, D, additional, Berkowitz, SD, additional, Berlingieri, J, additional, Berrios, W, additional, Berrouschot, J, additional, Bhandari, M, additional, Bhargavah, M, additional, Bicker, H, additional, Bicsak, T, additional, Bilik, M, additional, Bindila, D, additional, Birchenall, J, additional, Birnbaum, L, additional, Black, T, additional, Blacker, D, additional, Blacquiere, D, additional, Blanc-Labarre, C, additional, Blank, C, additional, Blazejewska-Hyzorek, B, additional, Bloch, S, additional, Bodiguel, E, additional, Bogdanov, E, additional, Boos, L, additional, Borcsik, L, additional, Bornstein, N, additional, Bouly, S, additional, Braga, G, additional, Bragado, I, additional, Bravi, MC, additional, Brokalaki, C, additional, Brola, W, additional, Brouns, R, additional, Bruce, D, additional, Brzoska-Mizgalska, J, additional, Buck, B, additional, Buksinska-Lisik, M, additional, Burke, J, additional, Burn, M, additional, Bustamante, G, additional, Cabrejo, L, additional, Cai, K, additional, Cajaraville, S, additional, Calejo, M, additional, Calvet, D, additional, Campillo, J, additional, Campos Costa, E, additional, Camps, P, additional, Can Alaydin, H, additional, Candeloro, E, additional, Canepa, C, additional, Cantu Brito, CG, additional, Cappellari, M, additional, Carcel, C, additional, Cardona Portela, P, additional, Cardoso, F, additional, Carek, M, additional, Carletti, M, additional, Carlos Portilla, J, additional, Caruso, P, additional, Casado-Naranjo, I, additional, Castellini, P, additional, Castro, D, additional, Castro Meira, F, additional, Cavallini, A, additional, Cayuela Caudevilla, N, additional, Cenciarelli, S, additional, Cereda, C, additional, Cerrone, P, additional, Chakrabarti, A, additional, Chaloulos-Iakovidis, P, additional, Chamorro, A, additional, Chandrasena, D, additional, Chang, DI, additional, Che, C, additional, Chembala, J, additional, Chen, J, additional, Chen, Z, additional, Chen, T, additional, Chen, H, additional, Chen, X, additional, Chen, G, additional, Chen, L, additional, Chen, S, additional, Cheripelli, B, additional, Chin, M, additional, Chiquete Anaya, E, additional, Chorazy, M, additional, Christensen, H, additional, Christensen, T, additional, Christian, L, additional, Chu, F, additional, Chung, CS, additional, Clark, W, additional, Clarke, R, additional, Claverie, S, additional, Clemente Agostoni, E, additional, Clissold, B, additional, Coelho, J, additional, Cohen, D, additional, Colakoglu, S, additional, Collas, D, additional, Condurso, R, additional, Connolly, SJ, additional, Consoli, D, additional, Constantin, C, additional, Constantino Silva, AB, additional, Contardo, L, additional, Corlobe, A, additional, Correia, M, additional, Correia, C, additional, Cortijo Garcia, E, additional, Coull, B, additional, Coutts, S, additional, Coveney, S, additional, Cras, P, additional, Crols, R, additional, Crozier, S, additional, Csanyi, A, additional, Csiba, L, additional, Csontos, K, additional, Csuha, R, additional, Cui, L, additional, Cunha, L, additional, Curtze, S, additional, Czerska, M, additional, Czlonkowska, A, additional, Czurko, M, additional, Czuryszkiewicz, M, additional, Dagnino, M, additional, Dai, C, additional, Daineko, A, additional, Dalek, G, additional, Damgaard, D, additional, Danese, A, additional, Dani, K, additional, Danku, V, additional, Dario Toledo, W, additional, Dávalos, A, additional, De Havenon, A, additional, De Keyser, J, additional, De Klippel, N, additional, De La Torre, J, additional, De Pauw, A, additional, De Smedt, A, additional, De Torres, R, additional, De Vries Basson, MM, additional, Dearborn, J, additional, Deganutto, R, additional, Degeorgia, M, additional, Deguchi, I, additional, Del Giudice, A, additional, Delcourt, C, additional, Delgado-Mederos, R, additional, Della Marca, G, additional, Delpont, B, additional, Deltour, S, additional, Demets, DL, additional, Dennis, M, additional, Desai, J, additional, Devine, J, additional, Dhollander, I, additional, Di Mascio, MT, additional, Diaconu, M, additional, Diaz Otero, F, additional, Dietzel, J, additional, Diez-Tejedor, E, additional, Ding, N, additional, Ding, J, additional, Diomedi, M, additional, Dioszeghy, P, additional, Distefano, M, additional, Domigo, V, additional, Dorodnicov, E, additional, Dossi, D, additional, Doubal, F, additional, Druzenko, I, additional, Du, P, additional, Du, J, additional, Duman, T, additional, Duodu, Y, additional, Dutta, D, additional, Dylewicz, L, additional, Eckstein, J, additional, Ehrensperger, E, additional, Ehrlich, S, additional, Einer Allende, G, additional, Elena Halac, B, additional, Elyas, S, additional, Endres, M, additional, Engelbrecht, JM, additional, Engelter, S, additional, Epinat, M, additional, Eren, F, additional, Esbjornsson, M, additional, Escribano, B, additional, Escudero, I, additional, Esisi, B, additional, Essa, B, additional, Esterbauer, M, additional, Evans, N, additional, Eveson, D, additional, Fabio, S, additional, Fang, L, additional, Fanta, S, additional, Fares, M, additional, Fatar, M, additional, Faust, K, additional, Favate, A, additional, Fazekas, F, additional, Federica Denaro, M, additional, Fedin, A, additional, Felipe Amaya, P, additional, Feng, J, additional, Ferencova, K, additional, Fernanda Gilli, M, additional, Fernandez, MD, additional, Fernandez Pirrone, PN, additional, Fernandez Vera, J, additional, Ferrari, J, additional, Ferreira, A, additional, Ferreira Junior, G, additional, Fidler, M, additional, Field, D, additional, Field, T, additional, Figueroa, C, additional, Fiksa, J, additional, Filipov, A, additional, Firstenfeld, A, additional, Fisch, L, additional, Fischer, U, additional, Fisselier, M, additional, Fiszer, U, additional, Fluri, F, additional, Fortea, G, additional, Fotherby, K, additional, Fraczek, A, additional, France, E, additional, Freitas, G, additional, Frey, S, additional, Frick, M, additional, Friedman, A, additional, Friedrich, M, additional, Frisullo, G, additional, Fryze, W, additional, Fuentes Gimeno, B, additional, Fujigasaki, H, additional, Fukuyama, K, additional, Furlan, A, additional, Furlanis, G, additional, Furnace, J, additional, Gabriel, M, additional, Gabriel Reich, E, additional, Gagliardi, RJ, additional, Galati, F, additional, Galli Giqueauk, E, additional, Gallina, A, additional, Gallinella, E, additional, Gallo, J, additional, Gangadharan, S, additional, Gao, Y, additional, Garcia Lopez, R, additional, Garcia Pastor, A, additional, Garcia Sanchez, SM, additional, Garnauf, M, additional, Garnier, P, additional, Gasecki, D, additional, Gasic, K, additional, Gasiorek, K, additional, Gasser, S, additional, Gaugg, M, additional, Gebreyohanns, M, additional, Gebura, K, additional, Geng, J, additional, Geniz Clavijo, M, additional, Georg Haeusler, K, additional, Geran, R, additional, Geremek, M, additional, Gerocs, Z, additional, Ghia, D, additional, Giannandrea, D, additional, Giatsidis, F, additional, Gien Lopez, JA, additional, Gil Nunez, A, additional, Gimenez, L, additional, Giralt, E, additional, Glabinski, A, additional, Gladstone, D, additional, Gliem, M, additional, Gluszkiewicz, M, additional, Goddeau, R, additional, Gogoleva, E, additional, Gokce, M, additional, Goldemund, D, additional, Golikov, K, additional, Gomes Neto, A, additional, Gomez Schneider, M, additional, Gomez-Choco, M, additional, Gomis, M, additional, Gongora-Rivera, JF, additional, Gonysheva, Y, additional, Gonzalez, L, additional, Gonzalez Toledo, ME, additional, Gottschal, M, additional, Gozdzik, I, additional, Grabowski, S, additional, Graf, S, additional, Green, D, additional, Greer, D, additional, Gregorio, T, additional, Greisenegger, S, additional, Greshnova, I, additional, Griebe, M, additional, Grzesik, M, additional, Guan, J, additional, Guarda, S, additional, Gueguen, A, additional, Guidoux, C, additional, Guillermo Povedano, P, additional, Guillon, B, additional, Guiraudg, V, additional, Gunathilagan, G, additional, Guryanova, N, additional, Gusev, V, additional, Gustavo Persi, G, additional, Gutiérrez, R, additional, Guyler, P, additional, Gyuker, N, additional, Hachinski, V, additional, Hajas, A, additional, Hallevi, H, additional, Hankey, G, additional, Hankey, GJ, additional, Hanouskova, L, additional, Hao, L, additional, Haraguchi, K, additional, Haralur Sreekantaiah, Y, additional, Haratz, S, additional, Hargroves, D, additional, Harkness, K, additional, Harmel, P, additional, Harrasser, M, additional, Hart, RG, additional, Harvey, M, additional, Hasan, R, additional, Hasegawa, Y, additional, Hassan, A, additional, Hattori, M, additional, Hatzitolios, A, additional, Hauk, M, additional, Hayashi, T, additional, Hayhoe, H, additional, Hedna, VS, additional, Heine, M, additional, Held, V, additional, Hellwig, S, additional, Henkner, J, additional, Henninger, N, additional, Hermans, S, additional, Hernandez, J, additional, Herrero, D, additional, Hervieu-Begue, M, additional, Herzig, R, additional, Hicken, L, additional, Hieber, M, additional, Hill, M, additional, Hirose, M, additional, Hobeanu, MC, additional, Hobson, B, additional, Hochstetter, M, additional, Hoe Heo, J, additional, Hoffmann, M, additional, Holmstedt, C, additional, Hon, P, additional, Hong, KS, additional, Honma, Y, additional, Horev, A, additional, Horgan, G, additional, Horvath, L, additional, Horvath, M, additional, Hoyer, C, additional, Huang, D, additional, Huang, H, additional, Huber, B, additional, Huhtakangas, J, additional, Hussain, M, additional, Igarashi, S, additional, Iglesias Mohedano, AM, additional, Ignacio Tembl, J, additional, Impellizzeri, M, additional, Inanc, Y, additional, Ioli, P, additional, Irina Aniculaesei, A, additional, Ishida, K, additional, Itabashi, R, additional, Iversen, H, additional, Jagolino, A, additional, Jakab, K, additional, Jander, S, additional, Janka, H, additional, Jankovych, J, additional, Jansen, J, additional, Jasek, L, additional, Javier Alet, M, additional, Javor, L, additional, Jin, X, additional, Jing, P, additional, Joachim, B, additional, Joan Macleod, M, additional, Johnson, M, additional, Jose Martin, J, additional, Joyner, C, additional, Judit Szabo, K, additional, Jun-Oconnell, A, additional, Jura, R, additional, Kaczorowska, B, additional, Kadlcikova, J, additional, Kahles, T, additional, Kakaletsis, N, additional, Kakuk, I, additional, Kalinowska, K, additional, Kaminska, K, additional, Kaneko, C, additional, Kanellos, I, additional, Kapeller, P, additional, Kapica-Topczewska, K, additional, Karasz, O, additional, Karlinski, M, additional, Karlsson, JE, additional, Kasa, K, additional, Kashaeva, E, additional, Kasner, SE, additional, Kaste, M, additional, Kasza, J, additional, Katalin Iljicsov, A, additional, Katsurayama, M, additional, Kaur, S, additional, Kawanishi, M, additional, Kaygorodtseva, S, additional, Ke, K, additional, Kei, A, additional, Keilitz, J, additional, Kellner, J, additional, Kelly, P, additional, Kelly, S, additional, Kemlink, D, additional, Kerekgyarto, M, additional, Keskinarkaus, I, additional, Khairutdinova, D, additional, Khanna, A, additional, Khaw, A, additional, Kholopov, M, additional, Khoumri, C, additional, Kirpicheva, S, additional, Kirshner, H, additional, Kitagawa, K, additional, Kittner, S, additional, Kivioja, R, additional, Klein, F, additional, Kleindorfer, D, additional, Kleinig, T, additional, Klivenyi, P, additional, Knecht, S, additional, Kobayashi, Y, additional, Kobayashi, A, additional, Koch, M, additional, Koehler, L, additional, Koivu, M, additional, Kolianov, V, additional, Koltsov, I, additional, Kondo, T, additional, Konkov, I, additional, Kopecky, S, additional, Korompoki, E, additional, Korpela, J, additional, Kosarz-Lanczek, K, additional, Koutroubi, A, additional, Kovacs, K, additional, Kovacs, T, additional, Kovacs, H, additional, Kowalczyk, K, additional, Kowalska, M, additional, Krajickova, D, additional, Kral, M, additional, Krarup Hansen, C, additional, Kraska, J, additional, Krebs, S, additional, Krejci, V, additional, Kremer, C, additional, Kreuzpointer, R, additional, Krzyzanowska, M, additional, Kucken, D, additional, Kulakowska, A, additional, Kunzmann, J, additional, Kurenkova, N, additional, Kuris, A, additional, Kurkowska-Jastrzebska, I, additional, Kurtenkova, N, additional, Kurushina, O, additional, Kusnick, G, additional, Kustova, M, additional, Kuwashiro, T, additional, Kwan Cha, J, additional, Lago, A, additional, Lagutenko, M, additional, Lajos, B, additional, Lambeck, J, additional, Lamy, C, additional, Landolfi, A, additional, Lanfranconi, S, additional, Lang, W, additional, Lara Lezama, LB, additional, Lara Rodriguez, B, additional, Largo, T, additional, Lasek-Bal, A, additional, Latte, L, additional, Lauer, V, additional, Lavados, P, additional, Le Bouc, R, additional, Leal Cantu, R, additional, Lechner, H, additional, Lecouturier, K, additional, Leder, S, additional, Lee, J, additional, Lee, BC, additional, Leger, A, additional, Leira, E, additional, Leisse, I, additional, Leker, R, additional, Lembo, G, additional, Lenskaya, L, additional, Leyden, J, additional, Li, G, additional, Li, M, additional, Li, S, additional, Li, J, additional, Liamis, G, additional, Liang, H, additional, Liang, Z, additional, Ligot, N, additional, Lin, H, additional, Lindert, R, additional, Lindgren, A, additional, Linna, M, additional, Litwin, T, additional, Liu, K, additional, Liu, X, additional, Llull, L, additional, Lohninger, B, additional, Longoni, M, additional, Loomis, C, additional, Lopes, D, additional, Lopez Fernandez, M, additional, Lopez Garza, N, additional, Lord, A, additional, Louw, S, additional, Lovasz, R, additional, Lowenkopf, T, additional, Lu, Z, additional, Lubke-Detring, SC, additional, Luder, R, additional, Lujan, S, additional, Luo, B, additional, Lupinogina, L, additional, Luschin, G, additional, Lutsep, H, additional, Lvova, A, additional, Ly, J, additional, Grosse, G.M., additional, Ma, H, additional, Ma, C, additional, Machado, M, additional, Machado, C, additional, Macher, S, additional, Machetanz, J, additional, Macian-Montoro, F, additional, Mackey, E, additional, Mackey, A, additional, Maclean, G, additional, Maestre-Moreno, J, additional, Magadan, A, additional, Magyar, T, additional, Mahagney, A, additional, Majid, A, additional, Majjhoo, A, additional, Makaritsis, K, additional, Mandzia, J, additional, Mangas Guijarro, M, additional, Mangion, D, additional, Manios, E, additional, Mann, S, additional, Manning, L, additional, Manno, C, additional, Manuel Garcia, J, additional, Maqueda, V, additional, Mar Castellanos, M, additional, Mar Freijo, M, additional, Marando, C, additional, Marcela Lepera, S, additional, Marcos Couto, J, additional, Maria Bruera, G, additional, Maria Greco, L, additional, Maria Lorenzo, A, additional, Maria Obmann, S, additional, Maria Roa, A, additional, Marini, C, additional, Marinkovic, I, additional, Mario Sumay, G, additional, Mario Torres, C, additional, Marko, M, additional, Markova, S, additional, Markus, H, additional, Marsh, R, additional, Marsili, E, additional, Marta Esnaola, M, additional, Marta Moreno, J, additional, Marti-Fabregas, J, additional, Martina Angelocola, S, additional, Martínez Sánchez, P, additional, Martinez-Majander, N, additional, Martins, S, additional, Marzelik, O, additional, Mastrocola, S, additional, Matamala, G, additional, Matoltsy, A, additional, Matosevic, B, additional, Matsumoto, S, additional, Maud, A, additional, Mauri Cabdevila, G, additional, May, Z, additional, Mayasi, Y, additional, Mayr, A, additional, Mazzoli, T, additional, Mcarthur, K, additional, Mccullough, L, additional, Medina Pech, CE, additional, Medlin, F, additional, Mehdiratta, M, additional, Mehta, S, additional, Mehta, D, additional, Mehta, B, additional, Melis, M, additional, Melnikova, E, additional, Mendez, B, additional, Mendonca, T, additional, Mengual Chirifie, JJ, additional, Menon, N, additional, Mensch, A, additional, Meseguer, E, additional, Messe, S, additional, Metcalf, K, additional, Meyer, N, additional, Michas, F, additional, Micheletti, N, additional, Mikulik, R, additional, Milionis, H, additional, Miller, B, additional, Milling, T, additional, Minelli, C, additional, Minhas, J, additional, Minns, M, additional, Mircea, D, additional, Mishra, S, additional, Mismas, A, additional, Mistri, A, additional, Mitrovic, N, additional, Miyake, H, additional, Modrau, B, additional, Moey, A, additional, Molina, C, additional, Molina, J, additional, Molis, A, additional, Moller, J, additional, Molnar, S, additional, Moniche, F, additional, Monosi, C, additional, Monzani, V, additional, Moonis, M, additional, Morais, R, additional, Morales, L, additional, Morales, A, additional, Morar-Precup, D, additional, Moreton, F, additional, Moro, C, additional, Morozova, E, additional, Morton, M, additional, Morvan, T, additional, Morvan, E, additional, Motko, T, additional, Mowla, A, additional, Mozhejko, E, additional, Muddegowda, G, additional, Mudhar, O, additional, Mueller, T, additional, Muhl, C, additional, Muir, KW, additional, Mundl, H, additional, Munoz, S, additional, Murphy, C, additional, Murphy, S, additional, Murtuzova, A, additional, Musuka, T, additional, Mutzenbach, J, additional, Myint, M, additional, Mysliwy, W, additional, Naccarato, M, additional, Naeije, G, additional, Nagakane, Y, additional, Natarajan, I, additional, Navaratnam, D, additional, Nave, A, additional, Nazliel, B, additional, Nedeltchev, K, additional, Nel, J, additional, Nell, H, additional, Nemeth, R, additional, Nemeth, L, additional, Neto, O, additional, Ng, K, additional, Ngeh, J, additional, Nicolas Chialvo, L, additional, Nieminen, T, additional, Nikkanen, M, additional, Nikl, J, additional, Nikoforova, M, additional, Nishino, S, additional, Nishiyama, Y, additional, Njovane, X, additional, Nogawa, S, additional, Nombela, F, additional, Norrving, B, additional, Nosek, K, additional, Nowak, B, additional, Nowakowska-Sledz, E, additional, Ntaios, G, additional, Numminen, H, additional, Nunez, F, additional, Obadia, M, additional, Oberndorfer, S, additional, Obrezan, A, additional, Ochiai, J, additional, Oczkowski, W, additional, O'Donnell, MJ, additional, Odyniec, A, additional, Oh, K, additional, Ohira, M, additional, Okamoto, Y, additional, Okpala, M, additional, Okubo, S, additional, Olah, L, additional, Olavarria, V, additional, Oleszek, J, additional, Onat Demirci, N, additional, Ondar, V, additional, Ongun, G, additional, Ooyama, K, additional, Orosz, V, additional, Ortiz, R, additional, Osseby, G, additional, Österlund-Tauriala, E, additional, Ovesen, C, additional, Ozcekic Demirhan, S, additional, Ozdoba-Rot, J, additional, Ozturk, S, additional, Ozyurt, E, additional, Pablo Grecco, M, additional, Pablo Povedano, G, additional, Paciaroni, M, additional, Padiglioni, C, additional, Pagola, J, additional, Palasik, W, additional, Panczel, G, additional, Panos, L, additional, Papadopoulos, G, additional, Papadopoulou, E, additional, Papagiannis, A, additional, Papavasileiou, V, additional, Papina, M, additional, Pardo De Donlebun, JR, additional, Parisi, V, additional, Park, JM, additional, Pasten, J, additional, Patel, N, additional, Pavlik, O, additional, Pawelczyk, M, additional, Peacock, WF, additional, Pei, H, additional, Peisker, T, additional, Pena Sedna, LF, additional, Penn, A, additional, Pentek, S, additional, Pepper, E, additional, Pereira, L, additional, Perera, K, additional, Perez, Y, additional, Perez, S, additional, Perez Leguizamon, P, additional, Pernicka, M, additional, Perry, R, additional, Persico, A, additional, Pesant, Y, additional, Peska, S, additional, Peters, D, additional, Peters, G, additional, Pettigrew, L, additional, Phan, T, additional, Philippi, S, additional, Phinney, T, additional, Pico, F, additional, Pidal, A, additional, Piechowski-Jozwiak, B, additional, Pieroni, A, additional, Pineiro, S, additional, Piras, V, additional, Pizova, N, additional, Polanco, J, additional, Polin, M, additional, Polyakov, A, additional, Polychronopoulou, E, additional, Polymeris, A, additional, Popov, D, additional, Poppe, A, additional, Postorino, P, additional, Pozzerese, C, additional, Pradhan, M, additional, Prats, L, additional, Prazdnichkova, E, additional, Prendl, B, additional, Pretorius, M, additional, Profice, P, additional, Prokopenko, S, additional, Pudov, E, additional, Pujol Lereis, V, additional, Punzo Bravo, G, additional, Purroy, F, additional, Qiu, J, additional, Qu, X, additional, Quenardelle, V, additional, Quesada Garcia, H, additional, Radrizzani, L, additional, Radtke, A, additional, Raffelsberger, T, additional, Ramirez Moreno, JM, additional, Ramos-Estebanez, C, additional, Rani, A, additional, Rapantova, P, additional, Rashed, K, additional, Rasheed Nihara, A, additional, Rasmussen, J, additional, Redondo Robles, L, additional, Reif, M, additional, Reiner, P, additional, Rekova, P, additional, Renu, A, additional, Repetto, M, additional, Reyes, P, additional, Reyes Morales, S, additional, Rha, JH, additional, Ribeiro, J, additional, Ricci, S, additional, Richard, C, additional, Rigual, R, additional, Rinaldi, C, additional, Riveira Rodriguez, C, additional, Rizzato, B, additional, Robinson, TG, additional, Rocco, A, additional, Rodrigues, M, additional, Rodriguez, G, additional, Rodriguez Campello, A, additional, Rodriguez Lucci, F, additional, Rodriguez Yanez, M, additional, Roesler, C, additional, Roffe, C, additional, Roine, R, additional, Roine, S, additional, Roldan, A, additional, Romana Pezzella, F, additional, Romano, M, additional, Roos, JS, additional, Rosso, C, additional, Rostrup Kruuse, C, additional, Roth, Y, additional, Roukens, R, additional, Roveri, L, additional, Rozanski, D, additional, Rozniecki, J, additional, Rozsa, C, additional, Rudilosso, S, additional, Ruiz Ares, G, additional, Ruiz Franco, A, additional, Rum, G, additional, Ruuskanen, J, additional, Rybinnik, I, additional, Ryota, K, additional, Saarinen, J, additional, Saavedra, V, additional, Sabben, C, additional, Sabet, A, additional, Sagris, D, additional, Sahlas, J, additional, Sakai, N, additional, Salamanca, P, additional, Salgado, P, additional, Salig, S, additional, Salletmayr, T, additional, Salnikov, M, additional, Samoshkina, O, additional, Samson, Y, additional, Sanak, D, additional, Sànchez Cerón, M, additional, Santalucia, P, additional, Santamaria Cadavid, M, additional, Santiago, P, additional, Santo, G, additional, Sanz Cuesta, B, additional, Sargento, J, additional, Sarraj, A, additional, Sas, K, additional, Sas, A, additional, Satoshi, O, additional, Satsoglou, S, additional, Sattar, N, additional, Savitz, S, additional, Savopoulos, C, additional, Saw, J, additional, Sawicka, M, additional, Sawyer, R, additional, Scandura, T, additional, Schillinger, N, additional, Schindler, J, additional, Schlachetzki, F, additional, Schneider, I, additional, Schuppner, R, additional, Schurig, J, additional, Schwarzbach, CJ, additional, Sebejova, M, additional, Seidel, G, additional, Sekaran, L, additional, Selcuk, D, additional, Selvarajah, J, additional, Semerano, A, additional, Semjen, J, additional, Semushina, D, additional, Sen, S, additional, Seok Park, M, additional, Serena, J, additional, Serhat Tokgoz, O, additional, Serles, W, additional, Serrano, F, additional, Sevin, M, additional, Seynaeve, L, additional, Shah, S, additional, Shamalov, N, additional, Shang, T, additional, Sharma, M, additional, Sharrief, A, additional, Shazam Hussain, M, additional, Shchukin, I, additional, Shen, W, additional, Shepeleva, E, additional, Shinsuke, I, additional, Shmonin, A, additional, Shoamanesh, A, additional, Shuaib, A, additional, Shulga, A, additional, Sibolt, G, additional, Sibon, I, additional, Sicilia, I, additional, Siebert, M, additional, Sieczkowska, E, additional, Sila, C, additional, Silva, AA, additional, Silva, D, additional, Silva, P, additional, Silva, Y, additional, Silvestrini, M, additional, Simony, Z, additional, Simpkins, A, additional, Singh, B, additional, Sinha, D, additional, Sipos, I, additional, Skoda, O, additional, Skowron, P, additional, Skowronska, M, additional, Sliwinska, B, additional, Slonkova, J, additional, Smolkin, A, additional, Smyth, A, additional, Sobolewski, P, additional, Sobota, A, additional, Sohn, SI, additional, Soldatov, M, additional, Solganov, I, additional, Soloveva, L, additional, Solovyeva, E, additional, Sonntag, N, additional, Soors, P, additional, Sorgun, M, additional, Soriano, C, additional, Spence, D, additional, Spengos, K, additional, Sposato, L, additional, Staaf, G, additional, Stadler, K, additional, Stakhovskaya, L, additional, Stamatelopoulos, K, additional, Steinert, S, additional, Stetkarova, I, additional, Stiehm, M, additional, Stocker, R, additional, Stoinski, J, additional, Stoll, A, additional, Stotts, G, additional, Stumpp, A, additional, Sucapane, P, additional, Suenaga, T, additional, Sun, X, additional, Sundararajan, S, additional, Sung Kim, J, additional, Suzuki, H, additional, Svaneborg, N, additional, Szasz, G, additional, Szczuchniak, W, additional, Szczyrba, S, additional, Szegedi, N, additional, Szekely, A, additional, Szewczyk, Z, additional, Szilagyi, G, additional, Szlufik, S, additional, Szoboszlai, K, additional, Szpisjak, L, additional, Sztajzel, R, additional, Sztriha, L, additional, Ta Wil, SE, additional, Taggeselle, J, additional, Takamatsu, K, additional, Takao, M, additional, Taki, W, additional, Takizawa, S, additional, Talahma, M, additional, Tamayo, A, additional, Tan, J, additional, Tanne, D, additional, Tapanainen, A, additional, Tapiola, T, additional, Tarasiuk, J, additional, Tatlisumak, T, additional, Tayal, A, additional, Tcvetkova, S, additional, Teal, P, additional, Tejada Garcia, J, additional, Tejada Meza, H, additional, Tenora, D, additional, Terceno, M, additional, Terentiou, A, additional, Tezcan, S, additional, Thaler, D, additional, Thomson, A, additional, Thouvenot, E, additional, Tiainen, M, additional, Timberg, I, additional, Timsit, S, additional, Tinchon, A, additional, Tirschwell, D, additional, Togay Isikay, C, additional, Tokunaga, K, additional, Tolino, M, additional, Toloza, C, additional, Tomelleri, G, additional, Tomoyuki, K, additional, Tomppo, LM, additional, Tong, Z, additional, Tong, L, additional, Toni, D, additional, Torres, J, additional, Tossavainen, C, additional, Toth, G, additional, Tountopoulou, A, additional, Touze, E, additional, Tovar, M, additional, Toyoda, K, additional, Trillo, S, additional, Trommer, A, additional, Tropepi, D, additional, Tryambake, D, additional, Tu, H, additional, Tuetuencue, S, additional, Tumova, R, additional, Tumpula, O, additional, Turc, G, additional, Tutaj, A, additional, Tynkkynen, J, additional, Uchiyama, S, additional, Uchwat, U, additional, Uhrinyakova, L, additional, Ulku Acar, R, additional, Uluduz Ugurlu, D, additional, Urra, X, additional, Urui, S, additional, Usero Ruiz, M, additional, Vaclavik, D, additional, Vahedi, K, additional, Valikovics, A, additional, Valpas, J, additional, Van Acker, P, additional, Van Daele, W, additional, Vanderschueren, G, additional, Vanina Jure, L, additional, Varela, R, additional, Varga, Z, additional, Varvat, J, additional, Varvyanskaya, N, additional, Vasco Salgado, A, additional, Vasko, P, additional, Vass, L, additional, Vassilopoulou, S, additional, Vastagh, I, additional, Vazquez, P, additional, Vecsei, L, additional, Veltkamp, R, additional, Venti, M, additional, Verdugo, M, additional, Verocai, V, additional, Veronica Marroquin, M, additional, Veronica Simonsini, C, additional, Veverka, T, additional, Vigl, M, additional, Vila, A, additional, Vilar, C, additional, Villanueva Osorio, JA, additional, Virta, J, additional, Vitkova, E, additional, Voglsperger, B, additional, Volna, J, additional, Von Weitzel-Mudersbach, PA, additional, Vora, N, additional, Voznyuk, I, additional, Wach-Klink, A, additional, Wacongne, A, additional, Walters, D, additional, Wang, Y, additional, Wang, J, additional, Wang, L, additional, Wang, X, additional, Wang, W, additional, Wang, N, additional, Wang, D, additional, Wang, H, additional, Warnack, W, additional, Wartenberg, K, additional, Waters, R, additional, Waters, M, additional, Webb, T, additional, Weber, J, additional, Weiss, G, additional, Weissenborn, K, additional, Weitz, JI, additional, Weller, B, additional, Wen, G, additional, Weng, G, additional, Werner, P, additional, Werring, D, additional, Wester, P, additional, Whiteley, W, additional, Whiting, R, additional, Wijeratne, T, additional, Willems, C, additional, Wilson, L, additional, Wilson, C, additional, Winder, T, additional, Windt, J, additional, Winkler, A, additional, Winska-Tereszkiewicz, A, additional, Wisniewska, A, additional, Wittayer, M, additional, Wlodek, A, additional, Wojnarowska-Arendt, A, additional, Wolf, M, additional, Wolff, V, additional, Wolter, C, additional, Wong, A, additional, Wook Nah, H, additional, Worthmann, H, additional, Wu, W, additional, Wu, S, additional, Wunderlich, S, additional, Wurzinger, H, additional, Wyse, DG, additional, Xiao, B, additional, Xiaopeng, W, additional, Ximenez-Carrillo, A, additional, Xiong, L, additional, Xiong, Y, additional, Xiong, W, additional, Xu, Y, additional, Xu, J, additional, Xu, Z, additional, Yalo, B, additional, Yamada, T, additional, Yamasaki, M, additional, Yang, L, additional, Yang, Y, additional, Yang, X, additional, Yang, Q, additional, Yang, B, additional, Yang, J, additional, Yasuhiro, I, additional, Yee Lam, M, additional, Yegappan, C, additional, Yip, S, additional, Ylikallio, E, additional, Ylikotila, P, additional, Yongwon Jin, A, additional, Yoon, BW, additional, Yoshida, Y, additional, Yperzeele, L, additional, Yuan, H, additional, Yuasa, H, additional, Zalewska, J, additional, Zanferrari, C, additional, Zapata, E, additional, Zboznovits, D, additional, Zelenka, I, additional, Zhang, C, additional, Zhang, B, additional, Zhang, S, additional, Zhang, M, additional, Zhang, X, additional, Zhang, J, additional, Zhao, L, additional, Zhirnova, O, additional, Zhou, L, additional, Zielinska-Turek, J, additional, Zinchenko, I, additional, Ziomek, M, additional, Zitzmann, A, additional, Zweifler, R, additional, and Zwiernik, J, additional
Published: 2018
Full Text: View/download PDF

16. Prediction of Early Recurrent Thromboembolic Event and Major Bleeding in Patients with Acute Stroke and Atrial Fibrillation by a Risk Stratification Schema: The ALESSA Score Study

Author: Paciaroni, M. Agnelli, G. Caso, V. Tsivgoulis, G. Furie, K.L. Tadi, P. Becattini, C. Falocci, N. Zedde, M. Abdul-Rahim, A.H. Lees, K.R. Alberti, A. Venti, M. Acciarresi, M. D'Amore, C. Mosconi, M.G. Cimini, L.A. Procopio, A. Bovi, P. Carletti, M. Rigatelli, A. Cappellari, M. Putaala, J. Tomppo, L. Tatlisumak, T. Bandini, F. Marcheselli, S. Pezzini, A. Poli, L. Padovani, A. Masotti, L. Vannucchi, V. Sohn, S.-I. Lorenzini, G. Tassi, R. Guideri, F. Acampa, M. Martini, G. Ntaios, G. Karagkiozi, E. Athanasakis, G. Makaritsis, K. Vadikolias, K. Liantinioti, C. Chondrogianni, M. Mumoli, N. Consoli, D. Galati, F. Sacco, S. Carolei, A. Tiseo, C. Corea, F. Ageno, W. Bellesini, M. Colombo, G. Silvestrelli, G. Ciccone, A. Scoditti, U. Denti, L. Mancuso, M. Maccarrone, M. Orlandi, G. Giannini, N. Gialdini, G. Tassinari, T. De Lodovici, M.L. Bono, G. Rueckert, C. Baldi, A. D'Anna, S. Toni, D. Letteri, F. Giuntini, M. Lotti, E.M. Flomin, Y. Pieroni, A. Kargiotis, O. Karapanayiotides, T. Monaco, S. Baronello, M.M. Csiba, L. Szabó, L. Chiti, A. Giorli, E. Del Sette, M. Imberti, D. Zabzuni, D. Doronin, B. Volodina, V. Michel, P. Vanacker, P. Barlinn, K. Pallesen, L.-P. Kepplinger, J. Bodechtel, U. Gerber, J. Deleu, D. Melikyan, G. Ibrahim, F. Akhtar, N. Gourbali, V. Yaghi, S.
Abstract: Background and Purposes - This study was designed to derive and validate a score to predict early ischemic events and major bleedings after an acute ischemic stroke in patients with atrial fibrillation. Methods - The derivation cohort consisted of 854 patients with acute ischemic stroke and atrial fibrillation included in prospective series between January 2012 and March 2014. Older age (hazard ratio 1.06 for each additional year; 95% confidence interval, 1.00-1.11) and severe atrial enlargement (hazard ratio, 2.05; 95% confidence interval, 1.08-2.87) were predictors for ischemic outcome events (stroke, transient ischemic attack, and systemic embolism) at 90 days from acute stroke. Small lesions (≤1.5 cm) were inversely correlated with both major bleeding (hazard ratio, 0.39; P=0.03) and ischemic outcome events (hazard ratio, 0.55; 95% confidence interval, 0.30-1.00). We assigned to age ≥80 years 2 points and between 70 and 79 years 1 point; ischemic index lesion >1.5 cm, 1 point; severe atrial enlargement, 1 point (ALESSA score). A logistic regression with the receiver-operating characteristic graph procedure (C statistic) showed an area under the curve of 0.697 (0.632-0.763; P=0.0001) for ischemic outcome events and 0.585 (0.493-0.678; P=0.10) for major bleedings. Results - The validation cohort consisted of 994 patients included in prospective series between April 2014 and June 2016. Logistic regression with the receiver-operating characteristic graph procedure showed an area under the curve of 0.646 (0.529-0.763; P=0.009) for ischemic outcome events and 0.407 (0.275-0.540; P=0.14) for hemorrhagic outcome events. Conclusions - In acute stroke patients with atrial fibrillation, high ALESSA scores were associated with a high risk of ischemic events but not of major bleedings. © 2017 American Heart Association, Inc.
Published: 2017

17. Early recurrence and major bleeding in patients with acute ischemic stroke and atrial fibrillation treated with Non-Vitamin-K oral anticoagulants (RAF-NOACs) Study

Author: Paciaroni, M. Agnelli, G. Falocci, N. Tsivgoulis, G. Vadikolias, K. Liantinioti, C. Chondrogianni, M. Bovi, P. Carletti, M. Cappellari, M. Zedde, M. Ntaios, G. Karagkiozi, E. Athanasakis, G. Makaritsis, K. Silvestrelli, G. Lanari, A. Ciccone, A. Putaala, J. Tomppo, L. Tatlisumak, T. Abdul-Rahim, A.H. Lees, K.R. Alberti, A. Venti, M. Acciarresi, M. D'Amore, C. Becattini, C. Mosconi, M.G. Cimini, L.A. Soloperto, R. Masotti, L. Vannucchi, V. Lorenzini, G. Tassi, R. Guideri, F. Acampa, M. Martini, G. Sohn, S.-I. Marcheselli, S. Mumoli, N. De Lodovici, M.L. Bono, G. Furie, K.L. Tadi, P. Yaghi, S. Toni, D. Letteri, F. Tassinari, T. Kargiotis, O. Lotti, E.M. Flomin, Y. Mancuso, M. Maccarrone, M. Giannini, N. Bandini, F. Pezzini, A. Poli, L. Padovani, A. Scoditti, U. Denti, L. Consoli, D. Galati, F. Sacco, S. Carolei, A. Tiseo, C. Gourbali, V. Orlandi, G. Giuntini, M. Chiti, A. Giorli, E. Gialdini, G. Corea, F. Ageno, W. Bellesini, M. Colombo, G. Monaco, S. Baronello, M.M. Karapanayiotides, T. Caso, V.
Abstract: Background--The optimal timing to administer non-vitamin K oral anticoagulants (NOACs) in patients with acute ischemic stroke and atrial fibrillation is unclear. This prospective observational multicenter study evaluated the rates of early recurrence and major bleeding (within90 days)and their timing in patients with acute ischemic stroke and atrial fibrillation who received NOACs for secondary prevention. Methods and Results--Recurrence was defined as the composite of ischemic stroke, transient ischemic attack, and symptomatic systemic embolism, and major bleeding was defined as symptomatic cerebral and major extracranial bleeding. For the analysis, 1127 patients were eligible: 381 (33.8%) were treated with dabigatran, 366 (32.5%) with rivaroxaban, and 380 (33.7%) with apixaban. Patients who received dabigatran were younger and had lower admission National Institutes of Health Stroke Scale score and less commonly had a CHA2DS2-VASc score > 4 and less reduced renal function. Thirty-two patients (2.8%) had early recurrence, and 27 (2.4%) had major bleeding. The rates of early recurrence and major bleeding were, respectively, 1.8% and 0.5% in patients receiving dabigatran, 1.6% and 2.5% in those receiving rivaroxaban, and 4.0% and 2.9% in those receiving apixaban. Patients who initiated NOACs within 2 days after acute stroke had a composite rate of recurrence and major bleeding of 12.4%; composite rates were 2.1% for those who initiated NOACs between 3 and 14 days and 9.1% for those who initiated > 14 days after acute stroke. Conclusions--In patients with acute ischemic stroke and atrial fibrillation, treatment with NOACs was associated with a combined 5% rate of ischemic embolic recurrence and severe bleeding within 90 days. © 2017 The Authors.
Published: 2017

18. Sex-related differences in risk factors, type of treatment received and outcomes in patients with atrial fibrillation and acute stroke: results from the RAF-study (Recurrence and Cerebral Bleeding in Patients with Acute Ischemic Stroke and Atrial Fibrillation)

Author: Antonenko, K, Paciaroni, M, Agnelli, G, Falocci, N, Becattini, C, Marcheselli, S, Rueckert, C, Pezzini, A, Poli, L, Padovani, A, Csiba, L, Szabó, L, Sohn, Si, Tassinari, T, Abdul Rahim, A, Michel, P, Cordier, M, Vanacker, P, Remillard, S, Alberti, A, Venti, M, Acciarresi, M, D’Amore, C, Scoditti, U, Denti, L, Orlandi, G, Chiti, A, Gialdini, G, Bovi, P, Carletti, M, Rigatelli, A, Putaala, J, Tatlisumak, T, Masotti, L, Lorenzini, G, Tassi, R, Guideri, F, Martini, G, Tsivgoulis, G, Vadikolias, K, Papageorgiou, Sg, Corea, F, Del Sette, M, Ageno, W, De Lodovici, Ml, Bono, G, Baldi, A, D’Anna, S, Sacco, Simona, Carolei, A, Tiseo, C, Imberti, D, Zabzuni, D, Doronin, B, Volodina, V, Consoli, D, Galati, F, Pieroni, A, Toni, D, Monaco, S, Maimone Baronello, M, Barlinn, K, Pallesen, Lp, Kepplinger, J, Bodechtel, U, Gerber, J, Deleu, D, Melikyan, G, Ibrahim, F, Akhtar, N, Mosconi, Mg, Lees, Kr, and Caso, V.
Published: 2017

19. Prestroke CHA2DS2-VASc Score and Severity of Acute Stroke in Patients with Atrial Fibrillation: Findings from RAF Study

Author: Acciarresi, M. Paciaroni, M. Agnelli, G. Falocci, N. Caso, V. Becattini, C. Marcheselli, S. Rueckert, C. Pezzini, A. Morotti, A. Costa, P. Padovani, A. Csiba, L. Szabó, L. Sohn, S.-I. Tassinari, T. Abdul-Rahim, A.H. Michel, P. Cordier, M. Vanacker, P. Remillard, S. Alberti, A. Venti, M. D'Amore, C. Scoditti, U. Denti, L. Orlandi, G. Chiti, A. Gialdini, G. Bovi, P. Carletti, M. Rigatelli, A. Putaala, J. Tatlisumak, T. Masotti, L. Lorenzini, G. Tassi, R. Guideri, F. Martini, G. Tsivgoulis, G. Vadikolias, K. Liantinioti, C. Corea, F. Del Sette, M. Ageno, W. De Lodovici, M.L. Bono, G. Baldi, A. D'Anna, S. Sacco, S. Carolei, A. Tiseo, C. Imberti, D. Zabzuni, D. Doronin, B. Volodina, V. Consoli, D. Galati, F. Pieroni, A. Toni, D. Monaco, S. Baronello, M.M. Barlinn, K. Pallesen, L.-P. Kepplinger, J. Bodechtel, U. Gerber, J. Deleu, D. Melikyan, G. Ibrahim, F. Akhtar, N. Mosconi, M.G. Lees, K.R.
Subjects: cardiovascular diseases
Abstract: Background and Purpose The aim of this study was to investigate for a possible association between both prestroke CHA2DS2-VASc score and the severity of stroke at presentation, as well as disability and mortality at 90 days, in patients with acute stroke and atrial fibrillation (AF). Methods This prospective study enrolled consecutive patients with acute ischemic stroke, AF, and assessment of prestroke CHA2DS2-VASc score. Severity of stroke was assessed on admission using the National Institutes of Health Stroke Scale (NIHSS) score (severe stroke: NIHSS ≥10). Disability and mortality at 90 days were assessed by the modified Rankin Scale (mRS
Published: 2017

20. Sex-related differences in risk factors, type of treatment received and outcomes in patients with atrial fibrillation and acute stroke: Results from the RAF-study (Early Recurrence and Cerebral Bleeding in Patients with Acute Ischemic Stroke and Atrial Fibrillation)

Author: Antonenko, K. Paciaroni, M. Agnelli, G. Falocci, N. Becattini, C. Marcheselli, S. Rueckert, C. Pezzini, A. Poli, L. Padovani, A. Csiba, L. Szabó, L. Sohn, S.-I. Tassinari, T. Abdul-Rahim, A.H. Michel, P. Cordier, M. Vanacker, P. Remillard, S. Alberti, A. Venti, M. Acciarresi, M. D’Amore, C. Scoditti, U. Denti, L. Orlandi, G. Chiti, A. Gialdini, G. Bovi, P. Carletti, M. Rigatelli, A. Putaala, J. Tatlisumak, T. Masotti, L. Lorenzini, G. Tassi, R. Guideri, F. Martini, G. Tsivgoulis, G. Vadikolias, K. Papageorgiou, S.G. Corea, F. Sette, M.D. Ageno, W. Lodovici, M.L.D. Bono, G. Baldi, A. D’Anna, S. Sacco, S. Carolei, A. Tiseo, C. Imberti, D. Zabzuni, D. Doronin, B. Volodina, V. Consoli, D. Galati, F. Pieroni, A. Toni, D. Monaco, S. Baronello, M.M. Barlinn, K. Pallesen, L.-P. Kepplinger, J. Bodechtel, U. Gerber, J. Deleu, D. Melikyan, G. Ibrahim, F. Akhtar, N. Mosconi, M.G. Lees, K.R. Caso, V.
Subjects: cardiovascular diseases
Abstract: Introduction: Atrial fibrillation is an independent risk factor of thromboembolism. Women with atrial fibrillation are at a higher overall risk for stroke compared to men with atrial fibrillation. The aim of this study was to evaluate for sex differences in patients with acute stroke and atrial fibrillation, regarding risk factors, treatments received and outcomes. Methods: Data were analyzed from the “Recurrence and Cerebral Bleeding in Patients with Acute Ischemic Stroke and Atrial Fibrillation” (RAF-study), a prospective, multicenter, international study including only patients with acute stroke and atrial fibrillation. Patients were followed up for 90 days. Disability was measured by the modified Rankin Scale (0–2 favorable outcome, 3–6 unfavorable outcome). Results: Of the 1029 patients enrolled, 561 were women (54.5%) (p < 0.001) and younger (p < 0.001) compared to men. In patients with known atrial fibrillation, women were less likely to receive oral anticoagulants before index stroke (p = 0.026) and were less likely to receive anticoagulants after stroke (71.3% versus 78.4%, p = 0.01). There was no observed sex difference regarding the time of starting anticoagulant therapy between the two groups (6.4 ± 11.7 days for men versus 6.5 ± 12.4 days for women, p = 0.902). Men presented with more severe strokes at onset (mean NIHSS 9.2 ± 6.9 versus 8.1 ± 7.5, p < 0.001). Within 90 days, 46 (8.2%) recurrent ischemic events (stroke/TIA/systemic embolism) and 19 (3.4%) symptomatic cerebral bleedings were found in women compared to 30 (6.4%) and 18 (3.8%) in men (p = 0.28 and p = 0.74). At 90 days, 57.7% of women were disabled or deceased, compared to 41.1% of the men (p < 0.001). Multivariate analysis did not confirm this significance. Conclusions: Women with atrial fibrillation were less likely to receive oral anticoagulants prior to and after stroke compared to men with atrial fibrillation, and when stroke occurred, regardless of the fact that in our study women were younger and with less severe stroke, outcomes did not differ between the sexes. © 2016, © European Stroke Organisation 2016.
Published: 2017

21. A 12-month prospective, observational study evaluating the impact of disease-modifying treatment on emotional burden in recently-diagnosed multiple sclerosis patients: The POSIDONIA study

Author: Montanari, E., Rottoli, M., Maimone, D., Confalonieri, P., Plewnia, K., Frigo, M., Francia, A., Pala, A., Losignore, N. A., Ragonese, P., Veneziano, A., Traccis, S., Bosco, G., Dotta, M., Severi, S., Ragno, M., Candeago, R. M., Feleppa, M., Stecchi, S., Bosco, D., Tola, M. R., Massacesi, Luca, Costantino, G., Solaro, C. M., Serrati, C., Totaro, R., Coniglio, M. G., Scarpini, E., Zuliani, C., Perla, F., Ticca, A., Cottone, S., Iudice, A., Koudriavteva, T., Di Battista, G., Gasperini, C., Perin, C., Meola, G., Pugliatti, M., Bandini, F., Cavalla, P., Posteraro, F., Consoli, D., Montanari E, Rottoli M, Maimone D, Confalonieri P, Plewnia K, Frigo M, Francia A, Pala A, Losignore NA, Ragonese P, Veneziano A, and POSIDONIA study group
Subjects: Male, Psychometrics, Anxiety, Hospital Anxiety and Depression Scale, 0302 clinical medicine, Immunologic Factor, Multiple sclerosis, Disease-modifying treatment, Emotional burden, Anxiety, Depression, Multiple Sclerosi, Disease-modifying treatment, 030212 general & internal medicine, Prospective Studies, Prospective cohort study, Depression (differential diagnoses), Depression, Middle Aged, Psychiatric Status Rating Scale, Treatment Outcome, Italy, Neurology, Female, Settore MED/26 - Neurologia, medicine.symptom, Psychology, Psychometric, Human, Adult, medicine.medical_specialty, Multiple Sclerosis, Mood Disorder, Adolescent, Logistic Model, 03 medical and health sciences, Young Adult, Rating scale, medicine, Humans, Immunologic Factors, Aged, Psychiatric Status Rating Scales, Mood Disorders, medicine.disease, Prospective Studie, Logistic Models, Mood disorders, Physical therapy, Emotional burden, Observational study, Neurology (clinical), 030217 neurology & neurosurgery
Abstract: Introduction Depression and anxiety are common among patients with multiple sclerosis (MS) and are frequently present at the time of MS diagnosis. Methods POSIDONIA was a 12-month, observational, prospective study conducted in Italy to evaluate the impact of disease-modifying treatment (DMT) on emotional burden in patients with recently-diagnosed MS. The Hospital Anxiety and Depression Scale (HADS), specifically HADS anxiety (HADS-A) and depression (HADS-D) subscale scores, the Short-Form 36 Health Survey (SF-36) and the Impact of Event Scale – Revised (IES-R) were used to measure patient-reported outcomes. The Hamilton Depression Rating Scale (HDRS), HDRS-17, was used as a measure of healthcare provider-reported outcomes. The primary study outcome was change from baseline in feelings of anxiety and depression over 12 months (via HADS). Results Of 250 enrolled patients, 222 (88.8%) completed the study. At baseline, mean HADS total, HADS-A and HADS-D subscale scores were within the normal range. There were no significant changes over time in mean HADS total and HADS-A and HADS-D subscale scores, although the subgroup of patients with baseline scores indicative of anxiety or depression tended to improve over time. Both the HDRS and IES-R total scores improved over time, but there were no statistically significant changes in SF-36. Conclusion In the patient population of the POSIDONIA study depression and anxiety were present in a minority of patients thus not allowing to detect the impact of starting DMT. However DMT appears to have a positive effect in patients with measurable anxiety or depression at baseline.
Published: 2016

22. Prognostic value of trans-thoracic echocardiography in patients with acute stroke and atrial fibrillation: findings from the RAF study

Author: Paciaroni, M. Agnelli, G. Falocci, N. Caso, V. Becattini, C. Marcheselli, S. Rueckert, C. Pezzini, A. Poli, L. Padovani, A. Csiba, L. Szabó, L. Sohn, S.-I. Tassinari, T. Abdul-Rahim, A.H. Michel, P. Cordier, M. Vanacker, P. Remillard, S. Alberti, A. Venti, M. Acciarresi, M. D’Amore, C. Mosconi, M.G. Scoditti, U. Denti, L. Orlandi, G. Chiti, A. Gialdini, G. Bovi, P. Carletti, M. Rigatelli, A. Putaala, J. Tatlisumak, T. Masotti, L. Lorenzini, G. Tassi, R. Guideri, F. Martini, G. Tsivgoulis, G. Vadikolias, K. Liantinioti, C. Corea, F. Del Sette, M. Ageno, W. De Lodovici, M.L. Bono, G. Baldi, A. D’Anna, S. Sacco, S. Carolei, A. Tiseo, C. Imberti, D. Zabzuni, D. Doronin, B. Volodina, V. Consoli, D. Galati, F. Pieroni, A. Toni, D. Monaco, S. Baronello, M.M. Barlinn, K. Pallesen, L.-P. Kepplinger, J. Bodechtel, U. Gerber, J. Deleu, D. Melikyan, G. Ibrahim, F. Akhtar, N. Lees, K.R.
Subjects: cardiovascular diseases
Abstract: Anticoagulant therapy is recommended for the secondary prevention of stroke in patients with atrial fibrillation (AF). The identification of patients at high risk for early recurrence, which are potential candidates to prompt anticoagulation, is crucial to justify the risk of bleeding associated with early anticoagulant treatment. The aim of this study was to evaluate in patients with acute ischemic stroke and AF the association between findings at trans-thoracic echocardiography (TTE) and 90 days recurrence. In consecutive patients with acute ischemic stroke and AF, TTE was performed within 7 days from hospital admission. Study outcomes were recurrent ischemic cerebrovascular events (stroke or TIA) and systemic embolism. 854 patients (mean age 76.3 ± 9.5 years) underwent a TTE evaluation; 63 patients (7.4 %) had at least a study outcome event. Left atrial thrombosis was present in 11 patients (1.3 %) among whom 1 had recurrent ischemic event. Left atrial enlargement was present in 548 patients (64.2 %) among whom 51 (9.3 %) had recurrent ischemic events. The recurrence rate in the 197 patients with severe left atrial enlargement was 11.7 %. On multivariate analysis, the presence of atrial enlargement (OR 2.13; 95 % CI 1.06–4.29, p = 0.033) and CHA2DS2-VASc score (OR 1.22; 95 % CI 1.04–1.45, p = 0.018, for each point increase) were correlated with ischemic recurrences. In patients with AF-associated acute stroke, left atrial enlargement is an independent marker of recurrent stroke and systemic embolism. The risk of recurrence is accounted for by severe atrial enlargement. TTE-detected left atrial thrombosis is relatively uncommon. © 2015, Springer-Verlag Berlin Heidelberg.
Published: 2016

23. Introduction: Sources and effects of medical innovation

Author: Consoli, D, Mina, Andrea, Nelson, R, and Ramlogan, R.
Published: 2016

24. Early recurrence and cerebral bleeding in patients with acute ischemic stroke and atrial fibrillation: Effect of anticoagulation and its timing: The RAF study

Author: Paciaroni, M. Agnelli, G. Falocci, N. Caso, V. Becattini, C. Marcheselli, S. Rueckert, C. Pezzini, A. Poli, L. Padovani, A. Csiba, L. Szabó, L. Sohn, S.-I. Tassinari, T. Abdul-Rahim, A.H. Michel, P. Cordier, M. Vanacker, P. Remillard, S. Alberti, A. Venti, M. Scoditti, U. Denti, L. Orlandi, G. Chiti, A. Gialdini, G. Bovi, P. Carletti, M. Rigatelli, A. Putaala, J. Tatlisumak, T. Masotti, L. Lorenzini, G. Tassi, R. Guideri, F. Martini, G. Tsivgoulis, G. Vadikolias, K. Liantinioti, C. Corea, F. Del Sette, M. Ageno, W. De Lodovici, M.L. Bono, G. Baldi, A. D'Anna, S. Sacco, S. Carolei, A. Tiseo, C. Acciarresi, M. D'Amore, C. Imberti, D. Zabzuni, D. Doronin, B. Volodina, V. Consoli, D. Galati, F. Pieroni, A. Toni, D. Monaco, S. Baronello, M.M. Barlinn, K. Pallesen, L.-P. Kepplinger, J. Bodechtel, U. Gerber, J. Deleu, D. Melikyan, G. Ibrahim, F. Akhtar, N. Mosconi, M.G. Bubba, V. Silvestri, I. Lees, K.R.
Abstract: Background and Purpose - The best time for administering anticoagulation therapy in acute cardioembolic stroke remains unclear. This prospective cohort study of patients with acute stroke and atrial fibrillation, evaluated (1) the risk of recurrent ischemic event and severe bleeding; (2) the risk factors for recurrence and bleeding; and (3) the risks of recurrence and bleeding associated with anticoagulant therapy and its starting time after the acute stroke. Methods - The primary outcome of this multicenter study was the composite of stroke, transient ischemic attack, symptomatic systemic embolism, symptomatic cerebral bleeding and major extracranial bleeding within 90 days from acute stroke. Results - Of the 1029 patients enrolled, 123 had 128 events (12.6%): 77 (7.6%) ischemic stroke or transient ischemic attack or systemic embolism, 37 (3.6%) symptomatic cerebral bleeding, and 14 (1.4%) major extracranial bleeding. At 90 days, 50% of the patients were either deceased or disabled (modified Rankin score ≥3), and 10.9% were deceased. High CHA2DS2-VASc score, high National Institutes of Health Stroke Scale, large ischemic lesion and type of anticoagulant were predictive factors for primary study outcome. At adjusted Cox regression analysis, initiating anticoagulants 4 to 14 days from stroke onset was associated with a significant reduction in primary study outcome, compared with initiating treatment before 4 or after 14 days: hazard ratio 0.53 (95% confidence interval 0.30-0.93). About 7% of the patients treated with oral anticoagulants alone had an outcome event compared with 16.8% and 12.3% of the patients treated with low molecular weight heparins alone or followed by oral anticoagulants, respectively (P=0.003). Conclusions - Acute stroke in atrial fibrillation patients is associated with high rates of ischemic recurrence and major bleeding at 90 days. This study has observed that high CHA2DS2-VASc score, high National Institutes of Health Stroke Scale, large ischemic lesions, and type of anticoagulant administered each independently led to a greater risk of recurrence and bleedings. Also, data showed that the best time for initiating anticoagulation treatment for secondary stroke prevention is 4 to 14 days from stroke onset. Moreover, patients treated with oral anticoagulants alone had better outcomes compared with patients treated with low molecular weight heparins alone or before oral anticoagulants. © 2015 American Heart Association, Inc.
Published: 2015

25. Erratum to: Prevalence of patent foramen ovale in ischemic stroke in Italy: the SISIFO Study (Neurol Sci (2014) 35, (867-873), 10.1007/s10072-013-1615-2)

Author: Consoli, D, Paciaroni, M, Aguggia, M, Melis, M, Malferrari, G, Vidale, S, Cerrato, P, Sacco, S, Gandolfo, C, Bovi, P, Serrati, C, Del Sette, M, Cavallini, A, Diomedi, M, Postorino, P, and Ricci, S
Subjects: Settore MED/26 - Neurologia, Settore MED/11 - Malattie dell'Apparato Cardiovascolare
Published: 2015

26. Intravenous thrombolysis or endovascular therapy for acute ischemic stroke associated with cervical internal carotid artery occlusion: the ICARO-3 study

Author: Paciaroni, M. Inzitari, D. Agnelli, G. Caso, V. Balucani, C. Grotta, J.C. Sarraj, A. Sung-Il, S. Chamorro, A. Urra, X. Leys, D. Henon, H. Cordonnier, C. Dequatre, N. Aguettaz, P. Alberti, A. Venti, M. Acciarresi, M. D’Amore, C. Zini, A. Vallone, S. Dell’Acqua, M.L. Menetti, F. Nencini, P. Mangiafico, S. Barlinn, K. Kepplinger, J. Bodechtel, U. Gerber, J. Bovi, P. Cappellari, M. Linfante, I. Dabus, G. Marcheselli, S. Pezzini, A. Padovani, A. Alexandrov, A.V. Shahripour, R.B. Sessa, M. Giacalone, G. Silvestrelli, G. Lanari, A. Ciccone, A. De Vito, A. Azzini, C. Saletti, A. Fainardi, E. Orlandi, G. Chiti, A. Gialdini, G. Silvestrini, M. Ferrarese, C. Beretta, S. Tassi, R. Martini, G. Tsivgoulis, G. Vasdekis, S.N. Consoli, D. Baldi, A. D’Anna, S. Luda, E. Varbella, F. Galletti, G. Invernizzi, P. Donati, E. De Lodovici, M.L. Bono, G. Corea, F. Sette, M.D. Monaco, S. Riva, M. Tassinari, T. Scoditti, U. Toni, D.
Abstract: The aim of the ICARO-3 study was to evaluate whether intra-arterial treatment, compared to intravenous thrombolysis, increases the rate of favourable functional outcome at 3 months in acute ischemic stroke and extracranial ICA occlusion. ICARO-3 was a non-randomized therapeutic trial that performed a non-blind assessment of outcomes using retrospective data collected prospectively from 37 centres in 7 countries. Patients treated with endovascular treatment within 6 h from stroke onset (cases) were matched with patients treated with intravenous thrombolysis within 4.5 h from symptom onset (controls). Patients receiving either intravenous or endovascular therapy were included among the cases. The efficacy outcome was disability at 90 days assessed by the modified Rankin Scale (mRS), dichotomized as favourable (score of 0–2) or unfavourable (score of 3–6). Safety outcomes were death and any intracranial bleeding. Included in the analysis were 324 cases and 324 controls: 105 cases (32.4 %) had a favourable outcome as compared with 89 controls (27.4 %) [adjusted odds ratio (OR) 1.25, 95 % confidence interval (CI) 0.88–1.79, p = 0.1]. In the adjusted analysis, treatment with intra-arterial procedures was significantly associated with a reduction of mortality (OR 0.61, 95 % CI 0.40–0.93, p = 0.022). The rates of patients with severe disability or death (mRS 5–6) were similar in cases and controls (30.5 versus 32.4 %, p = 0.67). For the ordinal analysis, adjusted for age, sex, NIHSS, presence of diabetes mellitus and atrial fibrillation, the common odds ratio was 1.15 (95 % IC 0.86–1.54), p = 0.33. There were more cases of intracranial bleeding (37.0 versus 17.3 %, p = 0.0001) in the intra-arterial procedure group than in the intravenous group. After the exclusion of the 135 cases treated with the combination of I.V. thrombolysis and I.A. procedures, 67/189 of those treated with I.A. procedures (35.3 %) had a favourable outcome, compared to 89/324 of those treated with I.V. thrombolysis (27.4 %) (adjusted OR 1.75, 95 % CI 1.00–3.03, p = 0.05). Endovascular treatment of patients with acute ICA occlusion did not result in a better functional outcome than treatment with intravenous thrombolysis, but was associated with a higher rate of intracranial bleeding. Overall mortality was significantly reduced in patients treated with endovascular treatment but the rates of patients with severe disability or death were similar. When excluding all patients treated with the combination of I.V. thrombolysis and I.A. procedures, a potential benefit of I.A. treatment alone compared to I.V. thrombolysis was observed. © 2014, Springer-Verlag Berlin Heidelberg.
Published: 2015

27. Battery Energy Storage and Advanced Forecast Integration in Large Scale PV Plant Enabling Active RES Integration in the Grid

Author: Lanuzza, L., Consoli, D., Bizzarri, F., Pregagnoli, C., Masci, D., Campagna, G., Mucci, D., Ercolani, L., Tommasi, V., and Fornaini, C.
Subjects: PV - A MAJOR ELECTRICITY SOURCE, PV in the Electricity Markets
Abstract: 31st European Photovoltaic Solar Energy Conference and Exhibition; 3099-3101, The increasing penetration of electricity generation from Renewable Energy Sources (RES) ask for an active integration of such sources in the grid. In this paper a project is presented aiming to propose and test solutions for such matters. During Q4-2014 the integration works of a NaNiCl2 battery energy storage system has been completed [1], the battery being installed in a 10MW PV power plant in Sicily. Activities of testing and performance monitoring are explained.
Published: 2015
Full Text: View/download PDF

28. Prevalence of patent foramen ovale in ischaemic stroke in italy: Results of SISIFO study

Author: Consoli, Domenico, Paciaroni, Maurizio, Galati, Franco, Aguggia, Marco, Melis, Maurizio, Malferrari, Giovanni, Consoli, Arturo, Vidale, Simone, Bosco, Domenico, Cerrato, Paolo, Sacco, Simona, Gandolfo, Carlo, Bovi, Paolo, Serrati, Carlo, Del Sette, Massimo, Cavallini, Anna, Postorino, Paolo, Reboldi, Paolo, Ricci, Stefano, Toni, D., Ricci, S., Micieli, G., Sterzi, R., Gensini, G. F., Comito, M., Consoli, D., Neri, G., Zarcone, D., Zaninelli, A., Franco, Giovanni Maria, Vecchio, Antonino, David, Piero, Orlando, Concetta, Francolino, Annabella, Grillo, Gaetano, Gattuso, Caterina, Comito, Michele, Cardona, Nicola, De Nardo, Alfredo, Tulino, Domenico, Arnaboldi, Marco, Sampietro, Alberto, Ricci, Silvia, Riga, Patrizia, Degan, Diana, Agnelli, Giancarlo, Acciarresi, Monica, Alberti, Andrea, Caso, Valeria, D'Amore, Cataldo, Venti, Michele, Balestrino, Maurizio, Bruno, Chiara, Finocchi, Cinzia, Massucco, Davide, Sassos, Davide, Viani, Erica, Reale, Nicoletta, Rizzi, Domenica, Brusa, Giulia, Ottonello, Gian Andrea, Carlino, Valeria, Cotroneo, Masina, Cibei, Eugenio, Gaeta, Roberta, Maregatti, Laura, Tartara, Elena, Spinelli, Maria Carmela, Lentini, Alessandra, Piras, Valeria, Moller, Jessica, Lilliu, Marzia, Fois, Vladimiro, Carletti, Monica, Luisa Zedde, Maria, Stanzione, Paolo, Diomedi, Marina, Carbotta, Giovanni, Cenciarelli, Silvia, Mattioni, Alessia, Gallinella, Elisabetta, Condurso, Rosaria, Sicilia, Isabella, Menichetti, Chiara, Conti, Lorenzo, and Cecconi, Stefano
Subjects: Male, medicine.medical_specialty, Pediatrics, Foramen Ovale, Patent, Cryptogenic stroke, Patent cardiac foramen ovale, Risk factor, Stroke epidemiology, Transcranial doppler ultrasound-embolus detection, Neurology (clinical), Neurology, Cardiology and Cardiovascular Medicine, Brain Ischemia, cryptogenic stroke, patent cardiac foramen ovale, risk factor, stroke epidemiology, transcranial doppler ultrasound-embolus detection, Risk Factors, Internal medicine, Ischaemic stroke, medicine, 80 and over, Prevalence, Humans, Prospective Studies, Stroke, Aged, Aged, 80 and over, Foramen ovale patent, business.industry, Brain, Foramen ovale (skull), Middle Aged, medicine.disease, medicine.anatomical_structure, Cross-Sectional Studies, Multicenter study, Italy, Patent foramen ovale, Cardiology, Settore MED/26 - Neurologia, Female, Patent, business, Foramen Ovale
Abstract: Background: Although several authors have studied the association between patent foramen ovale (PFO) and ischaemic stroke, the matter is still controversial; few have suggested an association between cryptogenetic stroke and PFO, while others have denied this association. The aim of this study was to evaluate PFO prevalence in the whole ischaemic stroke population, independently from age and stroke subtypes and to identify the characteristics associated with the presence of PFO. Methods: SISIFO study was a multicenter, prospective, single-wave, cross-sectional survey conducted on consecutive patients with acute ischemic stroke admitted to selected clinical centres. Data regarding vascular risk factors were registered for each patient; all patients underwent computed tomography scan and/or magnetic resonance imaging of the brain; an electrocardiogram and standard laboratory blood tests were performed. A Doppler ultrasound study of extra-cranial arteries was performed too. The cases were classified according to TOAST and OCSP criteria. Each patient underwent transcranial Doppler or transcranial color-coded duplex sonography with bubble test as diagnostic tool for right-to-left-shunt. Where right-to-left shunt was detected, PFO presence was confirmed by echocardiography. Findings: 1,130 consecutive patients were included. We found a PFO in 247 (21.9%; 95% CI, 19.5-24.3%) patients; PFO was present in 23.5% of patients with cryptogenic stroke and in 21.3% of patients with stroke of known causes; this difference was not statistically significant. At the univariate analysis, decreasing age, hypertension, diabetes mellitus, and atrial fibrillation, and stroke characteristics such as NIHSS, OCSP and TOAST were predictors of PFO presence. At the multivariate analysis, we found a significant interaction between age and OCSP syndrome. Being LACI the reference category, the prevalence of PFO in PACI and POCI decreased significantly along with age, whereas there was no change in TACI. Conclusion: If any relationship exists between stroke and PFO, this is more likely in PACI and POCI at a younger age. Our results are consistent with recent findings that underline PFO alone must not be considered a significant independent predictor for stroke; so the presence of PFO alone doesn't permit rushed causal correlations or ‘therapeutic aggressiveness'.
Published: 2015

29. Storage Technologies for Enabling Grid-tied Renewable Energy Sources to Grid ancillary Services Supply: a Successful Case.

Author: Tizzanini, A., Rambaldi, L., Lanuzza, L., Consoli, D., Bizzarri, F., De Cristofaro, A., and Fioretti, F.
Subjects: RENEWABLE energy sources, ENERGY storage, WIND power plants, ELECTRIC power distribution grids, ELECTRIC power production, ELECTRIC capacity
Abstract: In this paper, two integration experiences between renewable energy generation and energy storage systems have been analyzed. The experiences described are based on two different pilots: the Catania project (10 MWp PV, 1MW/2MWh Energy Storage) and Potenza Pietragalla project (18 MW wind farm, 2MW / 2MWh Energy Storage). The aim of the two projects described was to reduce peak power inputs due to a limited network capacity, the mitigation of imbalances associated with stochastic renewable generation, the optimization of input profiles due to market prices and the study of possible supply of ancillary services (primary, secondary reserve and voltage regulation) aggregating renewable generation and energy storage. The integrated power plants, demonstrated to have high global energy efficiency and good reliability. They have proven to be very effective in minimizing imbalances and optimizing power profiles, contributing to network reliability. [ABSTRACT FROM AUTHOR]
Published: 2017

30. Acid uric in acute ischemic stroke: The URICIS study

Author: Vidale, S., primary, Galati, F., additional, Ricci, S., additional, Postorino, P., additional, Perticone, F., additional, Arnaboldi, M., additional, and Consoli, D., additional
Published: 2015
Full Text: View/download PDF

31. Previous infection and the risk of ischaemic stroke in Italy: the IN2 study

Author: Consoli, D., primary, Vidale, S., additional, Aguglia, U., additional, Bassi, P., additional, Cavallini, A., additional, Galati, F., additional, Guidetti, D., additional, Marcello, N., additional, Micieli, G., additional, Pracucci, G., additional, Rasura, M., additional, Siniscalchi, A., additional, Sterzi, R., additional, Toni, D., additional, and Inzitari, D., additional
Published: 2014
Full Text: View/download PDF

32. Efecto del Boro sobre el rendimiento y la absorción de nutrientes en ajo.

Author: Lipinski, V. M., Valdés, A., Michieletti, A., Porta, A., Consoli, D., Lavanderos, D., Venier, M., and M. F.
Published: 2022

33. The trap of climate change-induced 'natural' disasters and inequality

Author: Federica Cappelli, Valeria Costantini, Davide Consoli, Cappelli, F., Costantini, V., Consoli, D., Ministero dell'Istruzione, dell'Università e della Ricerca, Ministerio de Ciencia, Innovación y Universidades (España), and Agencia Estatal de Investigación (España)
Subjects: Global and Planetary Change, Ecology, Inequality, media_common.quotation_subject, Geography, Planning and Development, Vulnerability, Climate change, Ambientale, Management, Monitoring, Policy and Law, Causality, Economica, Economic inequality, Simultaneous equations, Development economics, Climate change, Inequality, Natural disasters, System of simultaneous equations, Economics, Damages, Natural disasters, Natural disaster, System of simultaneous equations, media_common
Abstract: © 2022 The Authors, The purpose of the present paper is to disentangle the mechanisms that connect climate change-induced disasters, inequality and vulnerability by accounting for both directions of causality. We do so by means of a simultaneous equations approach on a panel of 149 countries from 1992 to 2018. The empirical analysis reveals that countries with higher levels of income inequality suffer greater damages when hit by a natural disaster. At the same time, inequality is found to increase the number of people affected by disasters. Our analysis discloses the existence of a vicious cycle that keeps some countries stuck in a disasters-inequality trap., FC and VC acknowledge the financial support of the Italian Ministry of University and Research (MIUR), Scientific Research Program of National Relevance PRIN2017 project “Innovation for global challenges in a connected world: the role of local resources and socio-economic conditions”. DC acknowledges the financial support of the Ministerio de Economía, Industria y Competitividad ‘Programa Estatal de I+D+i Orientada a los Retos de la Q2 Sociedad, 2017ʹ (ECO2017-86976-R).
Published: 2021

34. The PRIAMO study: age- and sex-related relationship between prodromal constipation and disease phenotype in early Parkinson’s disease

Author: L Grasso, Silvia Ramat, Simone Gallerini, Paolo Barone, G. Di Brigida, D. Fogli, Tommaso Scaravilli, M. Braga, Alessandra Nicoletti, M. Romeno, Paolo Martinelli, G. Gurgone, Cesare Colosimo, E. Pilleri, V. Sorbello, S. Amidei, F. Pennisi, Francesco Iemolo, Giorgio Trianni, Vincenzo Toni, E. Milan, Raffaele Palladino, D. Benincasa, Giovanni Pezzoli, M. G. Randisi, Alfredo Petrone, Arianna Guidubaldi, R. Alfano, Tania P. Avarello, A. Scaglioni, Anna Rita Bentivoglio, C. Modica, L. Ferigo, M. Manfredi, Domenico Consoli, Giuseppe Meco, Giampiero Volpe, S. Griffini, Francesca Morgante, R. Scala, G. Nordera, Angelo Antonini, G. Floris, Roberto Erro, R. Muoio, Salvatore Zappulla, Luigi Bartolomei, Edo Bottacchi, Antonio Pisani, V. Petretta, Giovanni Fabbrini, G. Ciacci, L. Maiello, G. Ceravolo, M. Di Giovanni, V. Nastasi, Rocco Quatrale, D. Tiple, Marcello Deriu, S. Lanfranchi, Marianna Capecci, Alberto Albanese, T. Cuomo, Francesco E. Pontieri, Vincenzo Moschella, G. Sciortino, F. A. De Falco, S. Biguzzi, Leonardo Lopiano, Marina Picillo, C. Alesi, D. De Gaspari, Michele Abrignani, Gabriella Santangelo, Fabrizio Stocchi, R. Luciano, M. Baratti, R. M. Giglia, Cesa Scaglione, B. Troianiello, Giovanni Abbruzzese, M. Mucchiut, F. Pepe, S. Zanini, L. Capus, N. Caravona, Giovanni Cossu, V. Agnetti, G. Albani, L. Kiferle, E. Giaccaglini, Roberto Marconi, M. Iellamo, R. Marano, D. Medici, Monica Ulivelli, G. A. Cocco, M. Perini, P. Del Dotto, Rosa M. Gaglio, Rodolfo Savica, C. Logi, G. Ciccarelli, P. Massimo, M. Pesare, Antonino Cannas, Roberto Ceravolo, P. Simone, Letterio Morgante, P. Soliveri, S. Meoni, Picillo, M., Palladino, R., Erro, R., Alfano, R., Colosimo, C., Marconi, R., Antonini, A., Barone, P., Morgante, L., Benincasa, D., Quatrale, R., Biguzzi, S., Braga, M., Ceravolo, G., Capecci, M., Meco, G., Caravona, N., Scala, R., De Falco, F. A., Pezzoli, G., De Gaspari, D., Bottacchi, E., Di Giovanni, M., Cannas, A., Floris, G., Gallerini, S., Grasso, L., Gaglio, R. M., Gurgone, G., Volpe, G., Zappulla, S., Ceravolo, R., Kiferle, L., Ramat, S., Meoni, S., Pisani, A., Moschella, V., Morgante, F., Savica, R., Pepe, F., Ciccarelli, G., Petretta, V., Giglia, R. M., Randisi, M. G., Iemolo, F., Avarello, T. P., Romeno, M., Santangelo, G., Stocchi, F., Sciortino, G., Sorbello, V., Nicoletti, A., Tiple, D., Fabbrini, G., Bentivoglio, A., Pontieri, F. E., Guidubaldi, A., Muoio, R., Toni, V., Del Dotto, P., Logi, C., Ciacci, G., Ulivelli, M., Perini, M., Lanfranchi, S., Griffini, S., Troianiello, B., Baratti, M., Amidei, S., Consoli, D., Iellamo, M., Cuomo, T., Scaglioni, A., Medici, D., Manfredi, M., Abbruzzese, G., Di Brigida, G., Cocco, G. A., Agnetti, V., Cossu, G., Deriu, M., Abrignani, M., Modica, C., Albani, G., Milan, E., Martinelli, P., Scaglione, C., Mucchiut, M., Zanini, S., Pennisi, F., Soliveri, P., Albanese, A., Massimo, P., Bartolomei, L., Capus, L., Ferigo, L., Marano, R., Nastasi, V., Luciano, R., Maiello, L., Simone, P., Fogli, D., Lopiano, L., Pesare, M., Nordera, G., Pilleri, E., Scaravilli, T., Giaccaglini, E., Alesi, C., Petrone, A., and Trianni, G.
Subjects: Male, Neurology, Parkinson's disease, Constipation, Heterogeneity, Parkinson, Phenotype, Prodromal, Sex, PROGRESSION, Disease, 0302 clinical medicine, Apathy, Neuroradiology, Original Communication, Cognition, Parkinson Disease, 030211 gastroenterology & hepatology, Female, medicine.symptom, NONMOTOR SYMPTOMS, Life Sciences & Biomedicine, PRIAMO study group, Human, medicine.medical_specialty, Clinical Neurology, Prodromal Symptoms, Prodromal Symptom, 03 medical and health sciences, Internal medicine, medicine, Humans, Clinical phenotype, Aged, Science & Technology, Neurology & Neurosurgery, business.industry, 1103 Clinical Sciences, Biomarker, medicine.disease, DYSFUNCTION, Biomarkers, Neurology (clinical), Neurosciences & Neurology, business, 1109 Neurosciences, 030217 neurology & neurosurgery
Abstract: Objectives To explore the impact of sex and age on relationship between prodromal constipation and disease phenotype in Parkinson’s disease at early stages. Methods A total of 385 Parkinson’s disease patients from the PRIAMO study were classified according to the presence of prodromal constipation and followed for 24 months. Multivariable mixed-effect models were applied. All analyses were performed separately for sex (64.1% men) and median age (different by sex: 67 years-old in men and 68 years-old in women). Results As for sex, prodromal constipation was associated with greater odds of attention/memory complaints and apathy symptoms in women only. As for age, prodromal constipation was associated with lower cognitive and higher apathy scores in older patients only. Conclusions Prodromal constipation anticipates lower cognitive performances and more severe apathy since the earliest stages in women and older patients. Sex- and age-related heterogeneity of prodromal markers of Parkinson’s disease may impact disease phenotype.
Published: 2021

35. Do neurologists agree in diagnosing drug resistance in adults with focal epilepsy?

Author: Stefano Meletti, Paolo Tinuper, Angela La Neve, Marco Mula, Maurizio Elia, Leila Zummo, Gaetano Zaccara, Domenico Consoli, Emilio Perucca, Bruno Ferrò, Alfonso Iudice, Anna Teresa Giallonardo, Zaccara G., Mula M., Ferro B., Consoli D., Elia M., Giallonardo A.T., Iudice A., La Neve A., Meletti S., Tinuper P., Zummo L., and Perucca E.
Subjects: Adult, Male, 0301 basic medicine, Drug Resistant Epilepsy, medicine.medical_specialty, Pediatrics, Neurology, Attitude of Health Personnel, Treatment outcome, antiepileptic drugs, classification, drug-resistant epilepsy, epilepsy, ILAE definition, reliability, Neurology (clinical), Drug resistance, 03 medical and health sciences, Epilepsy, antiepileptic drug, 0302 clinical medicine, medicine, Humans, Neurologists, Prospective Studies, Cooperative Behavior, business.industry, Middle Aged, medicine.disease, Confidence interval, Inter-rater reliability, 030104 developmental biology, Anticonvulsants, Female, Epilepsies, Partial, business, 030217 neurology & neurosurgery, Kappa
Abstract: Objective: To evaluate interrater agreement in categorizing treatment outcomes and drug responsiveness status according to the International League Against Epilepsy (ILAE) definition of drug-resistant epilepsy. Methods: A total of 1053 adults with focal epilepsy considered by the investigators to meet ILAE criteria for drug resistance were enrolled consecutively at 43 centers and followed up prospectively for 18-34months. Treatment outcomes for all antiepileptic drugs (AEDs) used up to enrollment (retrospective assessment), and on an AED newly introduced at enrollment, were categorized by individual investigators and by 2 rotating members of a 16-member expert panel (EP) that reviewed the patient records independently. Interrater agreement was tested by Cohen’s kappa (k) statistics and rated according to Landis and Koch’s criteria. Results: Agreement between EP members in categorizing outcomes on the newly introduced AED was almost perfect (90.1%, k=0.84, 95% confidence interval [CI] 0.80-0.87), whereas agreement between the EP and individual investigators was moderate (70.4%, k=0.57, 95% CI 0.53-0.61). Similarly, categorization of outcomes on previously used AEDs was almost perfect between EP members (91.7%, k=0.83, 95% CI 0.81-0.84) and moderate between the EP and investigators (68.2%, k=0.50, 95% CI 0.48-0.52). Disagreement was related predominantly to outcomes considered to be treatment failures by the investigators but categorized as undetermined by the EP. Overall, 19% of patients classified as having drug-resistant epilepsy by the investigators were considered by the EP to have “undefined responsiveness.”. Significance: Interrater agreement in categorizing treatment outcomes according to ILAE criteria ranges from moderate to almost perfect. Nearly 1 in 5 patients considered by enrolling neurologists to be “drug-resistant” were classified by the EP as having “undefined responsiveness.”.
Published: 2019

36. Land potential assessment and trend-analysis using 2000-2021 FAPAR monthly time-series at 250 m spatial resolution.

Author: Hackländer J, Parente L, Ho YF, Hengl T, Simoes R, Consoli D, Şahin M, Tian X, Jung M, Herold M, Duveiller G, Weynants M, and Wheeler I
Subjects: Humans, Agriculture, Seasons, Forests, Climate
Abstract: The article presents results of using remote sensing images and machine learning to map and assess land potential based on time-series of potential Fraction of Absorbed Photosynthetically Active Radiation (FAPAR) composites. Land potential here refers to the potential vegetation productivity in the hypothetical absence of short-term anthropogenic influence, such as intensive agriculture and urbanization. Knowledge on this ecological land potential could support the assessment of levels of land degradation as well as restoration potentials. Monthly aggregated FAPAR time-series of three percentiles (0.05, 0.50 and 0.95 probability) at 250 m spatial resolution were derived from the 8-day GLASS FAPAR V6 product for 2000-2021 and used to determine long-term trends in FAPAR, as well as to model potential FAPAR in the absence of human pressure. CCa 3 million training points sampled from 12,500 locations across the globe were overlaid with 68 bio-physical variables representing climate, terrain, landform, and vegetation cover, as well as several variables representing human pressure including: population count, cropland intensity, nightlights and a human footprint index. The training points were used in an ensemble machine learning model that stacks three base learners (extremely randomized trees, gradient descended trees and artificial neural network) using a linear regressor as meta-learner. The potential FAPAR was then projected by removing the impact of urbanization and intensive agriculture in the covariate layers. The results of strict cross-validation show that the global distribution of FAPAR can be explained with an R 2 of 0.89, with the most important covariates being growing season length, forest cover indicator and annual precipitation. From this model, a global map of potential monthly FAPAR for the recent year (2021) was produced, and used to predict gaps in actual vs . potential FAPAR. The produced global maps of actual vs . potential FAPAR and long-term trends were each spatially matched with stable and transitional land cover classes. The assessment showed large negative FAPAR gaps (actual lower than potential) for classes: urban, needle-leave deciduous trees, and flooded shrub or herbaceous cover, while strong negative FAPAR trends were found for classes: urban, sparse vegetation and rainfed cropland. On the other hand, classes: irrigated or post-flooded cropland, tree cover mixed leaf type, and broad-leave deciduous showed largely positive trends. The framework allows land managers to assess potential land degradation from two aspects: as an actual declining trend in observed FAPAR and as a difference between actual and potential vegetation FAPAR., Competing Interests: Julia Hackländer, Leandro Parente, Yu-Feng Ho, Tomislav Hengl, Rolf Simoes, Davide Consoli, Murat Şahin, Xuemeng Tian & Ichsani Wheeler are employed by OpenGeoHub., (© 2024 Hackländer et al.)
Published: 2024
Full Text: View/download PDF

37. Routinization, within-occupation task changes and long-run employment dynamics.

Author: Consoli D, Marin G, Rentocchini F, and Vona F
Abstract: The present study adds to the literature on routinization and employment by capturing within-occupation task changes over the period 1980-2010. The main contributions are the measurement of such changes and the combination of two data sources on occupational task content for the United States: the Dictionary of Occupational Titles (DOT) and the Occupational Information Network (O*NET). We show that within-occupation reorientation away from routine tasks: i) accounts for 1/3 of the decline in routine-task use; ii) accelerated in the 1990s, decelerated in the 2000s but with significant convergence across occupations; and iii) allowed workers to escape the employment and wage decline, conditional on the initial level of routine-task intensity. The latter finding suggests that task reorientation is a key channel through which labour markets adapt to various forms of labour-saving technological change., Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2022 The Authors.)
Published: 2023
Full Text: View/download PDF

38. Green innovation and income inequality: A complex system analysis.

Author: Napolitano L, Sbardella A, Consoli D, Barbieri N, and Perruchas F
Abstract: The objective of this paper is to analyse the relationship between income inequality and environmental innovation. To this end, we use the Economic Fitness and Complexity algorithm to compute an index of green inventive capacity in a panel of 57 countries over the period 1970-2010. The empirical analysis reveals that, on average, inequality is detrimental to countries' capacity to develop complex green technologies. Using non-parametric methods we further articulate this general finding and uncover interesting non-linearities in the relationship between innovation and inequality., (© 2022 The Author(s).)
Published: 2022
Full Text: View/download PDF

39. Influence of atrial fibrillation subtypes on anticoagulant therapy in a high-risk older population: the FAI project.

Author: Di Carlo A, Mori F, Consoli D, Bellino L, Zaninelli A, Baldereschi M, D'Alfonso MG, Gradia C, Cattarinussi A, Sgherzi B, Pracucci G, Piccardi B, Polizzi BM, and Inzitari D
Subjects: Administration, Oral, Aged, Aged, 80 and over, Anticoagulants therapeutic use, Cross-Sectional Studies, Factor Xa Inhibitors therapeutic use, Female, Humans, Male, Risk Factors, Atrial Fibrillation complications, Stroke epidemiology, Stroke etiology, Stroke prevention & control
Abstract: Background and Aim: Benefits of oral anticoagulants (OAC) in atrial fibrillation (AF) patients with moderate-to-high risk of stroke are independent of AF pattern. We evaluated whether AF clinical subtype influenced OAC use in a representative sample of the Italian older population., Methods: A cross-sectional examination of all subjects aged 65 + years from three general practices in northern, central, and southern Italy started in 2016. A double-screening procedure was followed by clinical and ECG confirmation. Patients were categorized as having paroxysmal, persistent, or permanent AF. OAC use was evaluated in confirmed AF patients., Results: The sample included 6016 subjects. Excluding 235 non-eligible, participation was 78.3%, which left 4528 participants (mean age 74.5 ± 6.8 years, 47.2% men). Overall, 319 AF cases were identified: 43.0% had paroxysmal, 21.3% persistent, and 35.7% permanent AF. Frequency of OAC therapy was 91.2% in permanent, 85.3% in persistent, and only 43.0% in paroxysmal AF (P < 0.001). In multivariate analysis, controlled for baseline variables and risk scales, persistent and permanent AF were associated with a significant increase in the likelihood of receiving OAC compared with paroxysmal AF (P < 0.001). This was confirmed for permanent AF also in multivariate analyses considering separately vitamin K antagonists or direct-acting oral anticoagulants (OR, 4.37, 95% CI, 2.43-7.85; and 1.92, 95% CI, 1.07-3.42, respectively) and for persistent AF and direct-acting oral anticoagulants (OR, 4.33, 95% CI, 2.30-8.15)., Conclusions: In a population-based survey, AF pattern was an independent predictor of OAC treatment. Paroxysmal AF is still perceived as carrying a lower risk of vascular events., (© 2022. The Author(s).)
Published: 2022
Full Text: View/download PDF

40. Brain-Computer Interfaces: Investigating the Transition from Visually Evoked to Purely Imagined Steady-State Potentials.

Author: Micheli A, Consoli D, Merlini A, Ricci P, and Andriulli FP
Subjects: Electroencephalography methods, Evoked Potentials, Visual, Humans, Imagination, Quality of Life, Brain-Computer Interfaces
Abstract: Brain-Computer Interfaces (BCIs) based on Steady State Visually Evoked Potentials (SSVEPs) have proven effective and provide significant accuracy and information-transfer rates. This family of strategies, however, requires external devices that provide the frequency stimuli required by the technique. This limits the scenarios in which they can be applied, especially when compared to other BCI approaches. In this work, we have investigated the possibility of obtaining frequency responses in the EEG output based on the pure visual imagination of SSVEP-eliciting stimuli. Our results show that not only that EEG signals present frequency-specific peaks related to the frequency the user is focusing on, but also that promising classification accuracy can be achieved, paving the way for a robust and reliable visual imagery BCI modality. Clinical relevance-Brain computer interfaces play a fundamental role in enhancing the quality of life of patients with severe motor impairments. Strategies based on purely imagined stimuli, like the one presented here, are particularly impacting, especially in the most severe cases.
Published: 2022
Full Text: View/download PDF

41. Fabry-Stroke Italian Registry (FSIR): a nationwide, prospective, observational study about incidence and characteristics of Fabry-related stroke in young-adults. Presentation of the study protocol.

Author: Romani I, Nencini P, Sarti C, Pracucci G, Zedde M, Nucera A, Cianci V, Moller J, Toni D, Orsucci D, Casella C, Pinto V, Palumbo P, Barbarini L, Bella R, Ragno M, Scoditti U, Mezzapesa DM, Tassi R, Diomedi M, Cavallini A, Volpi G, Chiti A, Bigliardi G, Sacco S, Linoli G, Ricci S, Giordano A, Bonetti B, Rasura M, Cecconi E, Princiotta Cariddi L, Currò Dossi R, Melis M, Consoli D, Guidetti D, Biagini S, Accavone D, and Inzitari D
Subjects: Adult, Humans, Incidence, Italy epidemiology, Middle Aged, Prospective Studies, Registries, Ischemic Attack, Transient diagnosis, Ischemic Attack, Transient epidemiology, Ischemic Attack, Transient etiology, Stroke diagnosis, Stroke epidemiology, Stroke etiology
Abstract: Background: TIA and stroke, both ischemic and hemorrhagic, may complicate Fabry disease at young-adult age and be the first manifestation that comes to the clinician's attention. No definite indications have yet been elaborated to guide neurologists in Fabry disease diagnostics. In current practice, it is usually sought in case of cryptogenic strokes (while Fabry-related strokes can also occur by classical pathogenic mechanisms) or through screening programs in young cerebrovascular populations. Data on recurrence and secondary prevention of Fabry's stroke are scanty., Methods: The study had a prospective observational design involving 33 Italian neurological Stroke Units. Considering the incidence of TIA/stroke in the European population aged < 60 years and the frequency of Fabry disease in this category (as foreseen by a pilot study held at the Careggi University-Hospital, Florence), we planned to screen for Fabry disease a total of 1740 < 60-year-old individuals hospitalized for TIA, ischemic, or hemorrhagic stroke. We investigated TIA and stroke pathogenesis through internationally validated scales and we gathered information on possible early signs of Fabry disease among all cerebrovascular patients. Every patient was tested for Fabry disease through dried blood spot analysis. Patients who received Fabry disease diagnosis underwent a 12-month follow-up to monitor stroke recurrence and multi-system progression after the cerebrovascular event., Discussion: The potential implications of this study are as follows: (i) to add information about the yield of systematic screening for Fabry disease in a prospective large cohort of acute cerebrovascular patients; (ii) to deepen knowledge of clinical, pathophysiological, and prognostic characteristics of Fabry-related stroke., (© 2021. The Author(s).)
Published: 2022
Full Text: View/download PDF

42. Altered synaptic glutamate homeostasis contributes to cognitive decline in young APP/PSEN1 mice.

Author: Wilcox JM, Consoli DC, Tienda AA, Dixit S, Buchanan RA, May JM, Nobis WP, and Harrison FE
Subjects: Animals, Electroencephalography, Epilepsy chemically induced, Epilepsy genetics, Female, Hippocampus drug effects, Hippocampus metabolism, Kainic Acid, Long-Term Potentiation, Maze Learning drug effects, Memory Disorders chemically induced, Memory Disorders psychology, Mice, Mice, Inbred C57BL, Plaque, Amyloid pathology, Amyloid beta-Protein Precursor genetics, Cognitive Dysfunction genetics, Cognitive Dysfunction metabolism, Glutamic Acid metabolism, Homeostasis physiology, Presenilin-1 genetics
Abstract: Non-convulsive epileptiform activity is a common and under-studied comorbidity of Alzheimer's disease that may significantly contribute to onset of clinical symptoms independently of other neuropathological features such as β-amyloid deposition. We used repeated treatment with low dose kainic acid (KA) to trigger sub-threshold epileptiform activity in young (less than 6 months) wild-type (WT) and APP/PSEN1 mice to test the role of disruption to the glutamatergic system in epileptiform activity changes and the development of memory deficits. Short-term repeated low-dose KA (five daily treatments with 5 mg/kg, IP) impaired long-term potentiation in hippocampus of APP/PSEN1 but not WT mice. Long-term repeated low-dose KA (fourteen weeks of bi-weekly treatment with 7.5-10 mg/kg) led to high mortality in APP/PSEN1 mice. KA treatment also impaired memory retention in the APP/PSEN1 mice in a Morris water maze task under cognitively challenging reversal learning conditions where the platform was moved to a new location. Four weeks of bi-weekly treatment with 5 mg/kg KA also increased abnormal spike activity in APP/PSEN1 and not WT mice but did not impact sleep/wake behavioral states. These findings suggest that hyperexcitability in Alzheimer's disease may indeed be an early contributor to cognitive decline that is independent of heavy β-amyloid-plaque load, which is absent in APP/PSEN1 mice under 6 months of age., (Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.)
Published: 2021
Full Text: View/download PDF

43. Distinguishing Fuzzballs from Black Holes through Their Multipolar Structure.

Author: Bianchi M, Consoli D, Grillo A, Morales JF, Pani P, and Raposo G
Abstract: Within general relativity, the unique stationary solution of an isolated black hole is the Kerr spacetime, which has a peculiar multipolar structure depending only on its mass and spin. We develop a general method to extract the multipole moments of arbitrary stationary spacetimes and apply it to a large family of horizonless microstate geometries. The latter can break the axial and equatorial symmetry of the Kerr metric and have a much richer multipolar structure, which provides a portal to constrain fuzzball models phenomenologically. We find numerical evidence that all multipole moments are typically larger (in absolute value) than those of a Kerr black hole with the same mass and spin. Current measurements of the quadrupole moment of black-hole candidates could place only mild constraints on fuzzballs, while future gravitational-wave detections of extreme mass-ratio inspirals with the space mission LISA will improve these bounds by orders of magnitude.
Published: 2020
Full Text: View/download PDF

44. Clinical RoPE (cRoPE) score predicts patent foramen ovale detection among stroke patients: a multicenter observational study.

Author: Giannandrea D, Padiglioni C, Eusebi P, Mengoni A, Romoli M, Galati F, Vecchio A, Cenciarelli S, Ricci S, and Consoli D
Subjects: Humans, Italy epidemiology, Prospective Studies, Reproducibility of Results, Risk Factors, Brain Ischemia diagnosis, Brain Ischemia diagnostic imaging, Embolism, Paradoxical, Foramen Ovale, Patent diagnosis, Foramen Ovale, Patent diagnostic imaging, Stroke diagnostic imaging, Stroke epidemiology
Abstract: Backgroud: The role of patent foramen ovale (PFO) in cryptogenic stroke (CS) is debated. Tools to predict PFO occurrence and attributable fraction are needed to guide cost-effective diagnostics and treatment. Risk of Paradoxical Embolism (RoPE) score relies on neuroimaging findings, which might be inconclusive in up to 30% of cases., Methods: We developed a clinical-based easy tool to predict the presence and attributable fraction of PFO in CS patients, without using neuroimaging. The clinical RoPE (cRoPE) score, ranging 1-10, was elaborated through Delphi method from the original RoPE score, replacing cortical infarction with the Oxfordshire Community Stroke Project (OCSP) classification (lacunar stroke = 0 points, other subtypes = 1 point). Then, from the SISIFO (Studio Italiano di prevalenza nello Stroke Ischemico di pervietà del Forame Ovale, or Prevalence of Patent Foramen Ovale in Ischemic Stroke in Italy) study, a multicenter, prospective study on consecutive acute ischemic stroke patients (n = 1130) classified by Trial of Org 10172 in Acute Stroke Treatment (TOAST) and OCSP criteria and undergoing PFO testing, we selected the VV-CDC cohort (Vibo Valentia, Città di Castello, n = 323) to test the accuracy of cRoPE in predicting PFO detection. We compared cRoPE with RoPE to verify cRoPE reliability. Finally, we tested, through ROC analysis, the performance of cRoPE depending on TOAST classification., Results: Overall, PFO was detected in 21% in VV-CDC and in 23.4% in remaining SISIFO cohort (n = 807). cRoPE AUC and RoPE AUC were similar in VV-CDC. cRoPE performance was comparable with RoPE among CS (cRoPE AUC 0.76, 95%CI 0.67-0.85, RoPE AUC 0.75, 95%CI 0.66-0.84). Moving to the remaining SISIFO cohort, cRoPE confirmed satisfactory accuracy in predicting PFO detection in CS patients (cRoPE AUC 0.71, 95%CI 0.66-0.78, p = 0.032)., Conclusions: Conclusions: cRoPE might help in stratification of patients with CS, allowing accurate esteem of the likelihood of PFO to be found, especially in cases when neuroimaging is inconclusive.
Published: 2020
Full Text: View/download PDF

45. Prevalence of Atrial Fibrillation Subtypes in Italy and Projections to 2060 for Italy and Europe.

Author: Di Carlo A, Zaninelli A, Mori F, Consoli D, Bellino L, Baldereschi M, Sgherzi B, Gradia C, DʼAlfonso MG, Cattarinussi A, Pracucci G, Piccardi B, Polizzi BM, and Inzitari D
Subjects: Age Distribution, Aged, Aged, 80 and over, Atrial Fibrillation classification, Cross-Sectional Studies, Electrocardiography, Europe epidemiology, Female, Humans, Italy epidemiology, Male, Mass Screening statistics & numerical data, Prevalence, Risk Assessment, Sex Distribution, Atrial Fibrillation epidemiology
Abstract: Background/objectives: Atrial fibrillation (AF) subtypes may carry different cardiovascular risk profiles, but information on their frequency from population-based studies is lacking. We estimated prevalence of AF subtypes in a representative sample of the Italian older population, projecting figures for Italy and the European Union., Design: Cross-sectional study., Setting: Three primary care practices in northern, central, and southern Italy., Participants: All individuals aged 65 years or older, for a total sample of 6,016 subjects. Excluding 235 noneligible, participation was 78.3%, which left 4,528 participants., Measurements: A double systematic and opportunistic screening procedure identified possible AF cases, followed by clinical and electrocardiogram confirmation. Patients were categorized with paroxysmal, persistent, or permanent AF. Prevalence was calculated by sex and 5-year age groups. Prevalence figures were applied to population projections for all 28 European Union states to estimate AF subtypes expected in future decades., Results: In the 4,528 participants (mean age = 74.5 ± 6.8 years; 47.2% men), 331 AF cases were identified: 140 (42.3%) paroxysmal, 77 (23.3%) persistent, and 114 (34.4%) permanent. Prevalence was 3.1% (95% confidence interval (CI) = 2.6%-3.6%) for paroxysmal, 1.7% (95% CI = 1.4%-2.1%) for persistent, and 2.5% (95% CI = 2.1%-3.0%) for permanent AF. Italian older persons having AF in 2016 were estimated at approximately 449,000 for paroxysmal, approximately 240,000 for persistent, and approximately 391,000 for permanent AF, projected to increase in 2060 to approximately 785,000, approximately 358,000, and approximately 748,000, respectively. European Union older persons having AF in 2016 were estimated at approximately 3,185,000 for paroxysmal, approximately 1,722,000 for persistent, and approximately 2,710,000 for permanent AF, projected to increase in 2060 to approximately 5,989,000, approximately 2,833,000, and approximately 5,579,000, respectively., Conclusion: We provided first projections of AF subtypes for Italy and Europe. The worse cardiovascular risk profile of persistent and permanent forms indicates an increased burden in future decades., (© 2020 The American Geriatrics Society.)
Published: 2020
Full Text: View/download PDF

46. Mortality in patients with intracerebral hemorrhage associated with antiplatelet agents, oral anticoagulants or no antithrombotic therapy.

Author: Franco L, Paciaroni M, Enrico ML, Scoditti U, Guideri F, Chiti A, De Vito A, Terruso V, Consoli D, Vanni S, Giossi A, Manina G, Nitti C, Re R, Sacco S, Cappelli R, Beyer-Westendorf J, Pomero F, Agnelli G, and Becattini C
Subjects: Cerebral Hemorrhage chemically induced, Cerebral Hemorrhage drug therapy, Fibrinolytic Agents adverse effects, Humans, Prospective Studies, Retrospective Studies, Anticoagulants adverse effects, Platelet Aggregation Inhibitors adverse effects
Abstract: The association between preceding treatment with antiplatelet agents (APs), vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) and mortality after intracerebral hemorrhage (ICH) remains unclear. The aim of this multicenter, prospective cohort study was to assess the risk for death after ICH in consecutive patients who were on treatment with APs, VKAs, DOACs, or no antithrombotic agent. The primary outcome was in-hospital death by day 30. ICH volume at admission and volume expansion were centrally assessed. Out of 598 study patients, in-hospital death occurred in 21% of patients who were on treatment with APs, 25% with VKAs, 30% with DOACs, and 13% with no antithrombotics. Crude death rate was higher in patients on antithrombotics as compared to patients receiving no antithrombotic agent. At multivariate analysis, age (HR 1.07; 95% CI 1.04-1.10), previous stroke (HR 1.83; 95% CI 1.14-2.93), GCS ≤8 at admission (HR 6.06; 95% CI 3.16-9.74) and GCS 9-12 (HR 3.38; 95% CI 1.81-6.33) were independent predictors of death. Treatment with APs (HR 1.29; 95% CI 0.61-2.76), VKAs (HR 1.42; 95% CI 0.70-2.88) or DOACs (HR 1.28; 95% CI 0.61-2.73) were not predictors of death in the overall study population, in non-trauma associated ICH as well as when GCS was not included in the model. ICH volume and volume expansion were independent predictors of death. In conclusion, preceding treatment with antithrombotic is associated with the severity of ICH. Age, previous stroke and clinical severity at presentation were independent predictors of in-hospital death in patients with ICH., Competing Interests: Disclosure of Conflict of interest Becattini C reports lectures fees from Boehringer Ingelheim and Bayer HealthCare. Beyer-Westendorf J has received honoraria and research support from Bayer HealthCare, Boehringer Ingelheim, Bristol-Myers Squibb, and Pfizer. Agnelli G reports lectures fees from Boehringer Ingelheim, from Sanofi, from Bayer HealthCare, and from Daiichi-Sankyo. The authors report no relationships that could be construed as a conflict of interest., (Copyright © 2019. Published by Elsevier B.V.)
Published: 2020
Full Text: View/download PDF

47. Bridging versus Direct Mechanical Thrombectomy in Acute Ischemic Stroke: A Subgroup Pooled Meta-Analysis for Time of Intervention, Eligibility, and Study Design.

Author: Vidale S, Romoli M, Consoli D, and Agostoni EC
Subjects: Aged, Aged, 80 and over, Brain Ischemia diagnosis, Brain Ischemia mortality, Brain Ischemia physiopathology, Eligibility Determination, Female, Humans, Male, Middle Aged, Recovery of Function, Risk Assessment, Risk Factors, Stroke diagnosis, Stroke mortality, Stroke physiopathology, Time Factors, Treatment Outcome, Brain Ischemia therapy, Clinical Decision-Making, Endovascular Procedures adverse effects, Endovascular Procedures mortality, Fibrinolytic Agents administration & dosage, Research Design, Stroke therapy, Thrombectomy adverse effects, Thrombolytic Therapy adverse effects, Thrombolytic Therapy mortality, Time-to-Treatment
Abstract: Background and Aim: The risk/benefit profile of intravenous thrombolysis (IVT) prior to endovascular thrombectomy (EVT) in acute ischemic stroke is still unclear. We provide a systematic review and meta-analysis including studies comparing direct EVT (dEVT) vs. bridging treatment (IVT + EVT), defining the impact of treatment timing and eligibility to IVT on functional status and mortality., Methods: Protocol was registered with PROSPERO (CRD42019135915) and followed PRISMA guidelines. PubMed, EMBASE, and Cochrane Central were searched for randomized controlled trials (RCTs), retrospective, and prospective studies comparing IVT + EVT vs. dEVT in adults (≥18) with acute ischemic stroke. Primary endpoint was functional independence at 90 days (modified Rankin Scale <3); secondary endpoints were (i) good recanalization (thrombolysis in cerebral infarction >2a), (ii) mortality, and (iii) symptomatic intracranial hemorrhage (sICH). Subgroup analysis was performed according to study type, eligibility to IVT, and onset-to-groin timing (OGT), stratifying studies for similar OGT. ORs for endpoints were pooled with meta-analysis and compared between reperfusion strategies., Results: Overall, 35 studies were included (n = 9,117). No significant differences emerged comparing patients undergoing dEVT and bridging treatment for gender, hypertension, diabetes, National Institute of Health Stroke Scale score at admission. Regarding primary endpoint, IVT + EVT was superior to dEVT (OR 1.44, 95% CI 1.22-1.69, p < 0.001, pheterogeneity<0.001), with number needed to treat being 18 in favor of IVT + EVT. Results were confirmed in studies with similar OGT (OR 1.66; 95% CI 1.21-2.28), shorter OGT for IVT + EVT (OR 1.53, 95% CI 1.27-1.85), and independently from IVT eligibility (OR 1.53, 95% CI 1.29-1.82). Mortality at 90 days was higher in dEVT (OR 1.38; 95% CI 1.09-1.75), but no significant difference was noted for sICH. However, considering data from RCT only, reperfusion strategies had similar primary (OR 0.91, 95% CI 0.6-1.39) and secondary endpoints. Differences in age and clinical severity across groups were unrelated to the primary endpoint., Conclusions: Compared to dEVT, IVT + EVT associates with better functional outcome and lower mortality. Post hoc data from RCTs point to substantial equivalence of reperfusion strategies. Therefore, an adequately powered RCTs comparing dEVT versus IVT + EVT are warranted., (© 2020 S. Karger AG, Basel.)
Published: 2020
Full Text: View/download PDF

48. Prevalence of atrial fibrillation in the Italian elderly population and projections from 2020 to 2060 for Italy and the European Union: the FAI Project.

Author: Di Carlo A, Bellino L, Consoli D, Mori F, Zaninelli A, Baldereschi M, Cattarinussi A, D'Alfonso MG, Gradia C, Sgherzi B, Pracucci G, Piccardi B, Polizzi B, and Inzitari D
Subjects: Age Distribution, Age Factors, Aged, Atrial Fibrillation complications, Atrial Fibrillation diagnosis, Cross-Sectional Studies, European Union, Female, Follow-Up Studies, Humans, Italy epidemiology, Male, Prevalence, Prospective Studies, Sex Distribution, Stroke epidemiology, Atrial Fibrillation epidemiology, Electrocardiography, Forecasting, Mass Screening methods, Stroke etiology
Abstract: Aims: To estimate prevalence of atrial fibrillation (AF) in a representative sample of the Italian elderly population, projecting figures for Italy and the European Union., Methods and Results: A cross-sectional examination of all subjects aged 65+ years from three general practices in Northern, Central, and Southern Italy started in 2016. Participants were administered a systematic and an opportunistic screening, followed by clinical and electrocardiogram confirmation. The study sample included 6016 subjects. Excluding 235 non-eligible, among the remaining 5781 participation was 78.3%, which left 4528 participants (mean age 74.5 ± 6.8 years, 47.2% men). Prevalence of AF was 7.3% [95% confidence intervals (CI) 6.6-8.1], higher in men and with advancing age (6.6% from systematic plus 0.7% from opportunistic screening). Using prevalence figures, Italian elderly having AF in 2016 were estimated at ∼1 081 000 (95% CI 786 000-1 482 000). Considering stable prevalence, this number will increase by 75% to ∼1 892 000 in 2060 (95% CI 1 378 000-2 579 000). European Union elderly having AF in 2016 were estimated at ∼7 617 000 (95% CI 5 530 000-10 460 000), increasing by 89% to ∼14 401 000 in 2060 (95% CI 10 489 000-19 647 000). In 2016, subjects aged 80+ years represented 53.5% of cases in Italy and 51.2% in the European Union; in 2060, 69.6% and 65.2%, respectively., Conclusions: Our findings indicate a high burden of AF in coming decades, especially among the oldest-old, who carry the higher AF-related risk of stroke and medical complications., (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.)
Published: 2019
Full Text: View/download PDF

49. Hypertension, seizures, and epilepsy: a review on pathophysiology and management.

Author: Gasparini S, Ferlazzo E, Sueri C, Cianci V, Ascoli M, Cavalli SM, Beghi E, Belcastro V, Bianchi A, Benna P, Cantello R, Consoli D, De Falco FA, Di Gennaro G, Gambardella A, Gigli GL, Iudice A, Labate A, Michelucci R, Paciaroni M, Palumbo P, Primavera A, Sartucci F, Striano P, Villani F, Russo E, De Sarro G, and Aguglia U
Subjects: Humans, Cerebral Small Vessel Diseases complications, Epilepsy etiology, Hypertension complications, Seizures etiology, Stroke complications
Abstract: Background: Epilepsy and hypertension are common chronic conditions, both showing high prevalence in older age groups. This review outlines current experimental and clinical evidence on both direct and indirect role of hypertension in epileptogenesis and discusses the principles of drug treatment in patients with hypertension and epilepsy., Methods: We selected English-written articles on epilepsy, hypertension, stroke, and cerebrovascular disease until December, 2018., Results: Renin-angiotensin system might play a central role in the direct interaction between hypertension and epilepsy, but other mechanisms may be contemplated. Large-artery stroke, small vessel disease and posterior reversible leukoencephalopathy syndrome are hypertension-related brain lesions able to determine epilepsy by indirect mechanisms. The role of hypertension as an independent risk factor for post-stroke epilepsy has not been demonstrated. The role of hypertension-related small vessel disease in adult-onset epilepsy has been demonstrated. Posterior reversible encephalopathy syndrome is an acute condition, often caused by a hypertensive crisis, associated with the occurrence of acute symptomatic seizures. Chronic antiepileptic treatment should consider the risk of drug-drug interactions with antihypertensives., Conclusions: Current evidence from preclinical and clinical studies supports the vision that hypertension may be a cause of seizures and epilepsy through direct or indirect mechanisms. In both post-stroke epilepsy and small vessel disease-associated epilepsy, chronic antiepileptic treatment is recommended. In posterior reversible encephalopathy syndrome blood pressure must be rapidly lowered and prompt antiepileptic treatment should be initiated.
Published: 2019
Full Text: View/download PDF

50. Anticoagulation After Stroke in Patients With Atrial Fibrillation.

Author: Altavilla R, Caso V, Bandini F, Agnelli G, Tsivgoulis G, Yaghi S, Furie KL, Tadi P, Becattini C, Zedde M, Abdul-Rahim AH, Lees KR, Alberti A, Venti M, Acciarresi M, D'Amore C, Mosconi MG, Anna Cimini L, Fusaro J, Bovi P, Carletti M, Rigatelli A, Cappellari M, Putaala J, Tomppo L, Tatlisumak T, Marcheselli S, Pezzini A, Poli L, Padovani A, Masotti L, Vannucchi V, Sohn SI, Lorenzini G, Tassi R, Guideri F, Acampa M, Martini G, Ntaios G, Athanasakis G, Makaritsis K, Karagkiozi E, Vadikolias K, Liantinioti C, Chondrogianni M, Mumoli N, Consoli D, Galati F, Sacco S, Carolei A, Tiseo C, Corea F, Ageno W, Bellesini M, Silvestrelli G, Ciccone A, Lanari A, Scoditti U, Denti L, Mancuso M, Maccarrone M, Ulivi L, Orlandi G, Giannini N, Gialdini G, Tassinari T, De Lodovici ML, Bono G, Rueckert C, Baldi A, D'Anna S, Toni D, Letteri F, Giuntini M, Maria Lotti E, Flomin Y, Pieroni A, Kargiotis O, Karapanayiotides T, Monaco S, Maimone Baronello M, Csiba L, Szabó L, Chiti A, Giorli E, Del Sette M, Imberti D, Zabzuni D, Doronin B, Volodina V, Michel P, Vanacker P, Barlinn K, Pallesen LP, Barlinn J, Deleu D, Melikyan G, Ibrahim F, Akhtar N, Gourbali V, and Paciaroni M
Subjects: Cerebral Hemorrhage epidemiology, Cerebral Hemorrhage etiology, Humans, Secondary Prevention, Stroke epidemiology, Stroke etiology, Anticoagulants therapeutic use, Atrial Fibrillation complications, Heparin, Low-Molecular-Weight therapeutic use, Stroke prevention & control
Abstract: Background and Purpose- Bridging therapy with low-molecular-weight heparin reportedly leads to a worse outcome for acute cardioembolic stroke patients because of a higher incidence of intracerebral bleeding. However, this practice is common in clinical settings. This observational study aimed to compare (1) the clinical profiles of patients receiving and not receiving bridging therapy, (2) overall group outcomes, and (3) outcomes according to the type of anticoagulant prescribed. Methods- We analyzed data of patients from the prospective RAF and RAF-NOACs studies. The primary outcome was defined as the composite of ischemic stroke, transient ischemic attack, systemic embolism, symptomatic cerebral bleeding, and major extracerebral bleeding observed at 90 days after the acute stroke. Results- Of 1810 patients who initiated oral anticoagulant therapy, 371 (20%) underwent bridging therapy with full-dose low-molecular-weight heparin. Older age and the presence of leukoaraiosis were inversely correlated with the use of bridging therapy. Forty-two bridged patients (11.3%) reached the combined outcome versus 72 (5.0%) of the nonbridged patients (P=0.0001). At multivariable analysis, bridging therapy was associated with the composite end point (odds ratio, 2.3; 95% CI, 1.4-3.7; P<0.0001), as well as ischemic (odds ratio, 2.2; 95% CI, 1.3-3.9; P=0.005) and hemorrhagic (odds ratio, 2.4; 95% CI, 1.2-4.9; P=0.01) end points separately. Conclusions- Our findings suggest that patients receiving low-molecular-weight heparin have a higher risk of early ischemic recurrence and hemorrhagic transformation compared with nonbridged patients.
Published: 2019
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

95 results on '"Consoli, D."'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources